WO2020051435A1 - Neuroprotective agents for treatment of neurodegenerative diseases - Google Patents
Neuroprotective agents for treatment of neurodegenerative diseases Download PDFInfo
- Publication number
- WO2020051435A1 WO2020051435A1 PCT/US2019/049927 US2019049927W WO2020051435A1 WO 2020051435 A1 WO2020051435 A1 WO 2020051435A1 US 2019049927 W US2019049927 W US 2019049927W WO 2020051435 A1 WO2020051435 A1 WO 2020051435A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- optionally substituted
- aryl
- alkenyl
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 14
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 title description 7
- 239000004090 neuroprotective agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 150000002148 esters Chemical class 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract description 12
- 125000001424 substituent group Chemical group 0.000 claims abstract description 12
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- 125000003118 aryl group Chemical group 0.000 claims description 43
- -1 biphenylyl Chemical group 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 53
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 38
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 33
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 229960003638 dopamine Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000012043 crude product Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- 208000018737 Parkinson disease Diseases 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 150000002430 hydrocarbons Chemical group 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 0 C*(C)c1c(C)c(*)c(*(C)(C)*)c(*)c1* Chemical compound C*(C)c1c(C)c(*)c(*(C)(C)*)c(*)c1* 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 2
- CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000003271 compound fluorescence assay Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001190 organyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- SLWIPPZWFZGHEU-UHFFFAOYSA-N 2-[4-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(CC(O)=O)C=C1 SLWIPPZWFZGHEU-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CSIFGMFVGDBOQC-UHFFFAOYSA-N 3-iminobutanenitrile Chemical compound CC(=N)CC#N CSIFGMFVGDBOQC-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 1
- 108050003506 ABL interactor 2 Proteins 0.000 description 1
- 102100028221 Abl interactor 2 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PWQFLEIGKAIACN-UHFFFAOYSA-N CC(CC1)Cc2c1nc(N)[s]2 Chemical compound CC(CC1)Cc2c1nc(N)[s]2 PWQFLEIGKAIACN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 101500014379 Lymnaea stagnalis Ovulation hormone Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030312 On and off phenomenon Diseases 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 229910008433 SnCU Inorganic materials 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000006739 dopaminergic cell death Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 108010024941 iodothyronine deiodinase type II Proteins 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to compounds for treating neurodegenerative diseases.
- Dopaminergic receptor systems have been targeted for the development of pharmaeotherapeulic agents for a number of CNS related disorders, including drug addiction, schizophrenia, depression, and Parkinson’s disease (PD).
- Dopamine (DA) receptor agonists have been employed more extensively in the treatment of Parkinson’s disease than any other type of pharmacotherapy.
- Levodopa L-dopa
- DA receptors belong to the family of transmembrane proteins known as G-protein-coupled receptors (GPCRs). DA receptors are widely distributed in the CNS, are also present in the periphery, and are divided into five subtypes.
- Dl and D5 are grouped together as Dl type.
- D2-D4 receptors are classified as D2 type because of their inhibitory action on adeny!yl cyclase activity.
- the D3 receptor was found to have a distribution in the brain that is somewhat different from that of the D2 receptor. The highest levels of D3 receptor expression were found to be in the limbic region of the brain, while D2 receptor expression is most dense i n the striatum of the midbrain.
- D2 and D3 receptor subtypes occur post- and presynapiically. In the latter location they function as autoreceptors that regulate DA synthesis, metabolism, and release. It is noteworthy that D2 and D3
- I receptor subtypes share 50% overall amino acid sequence homology and 75-80% in their agonist binding sites. As a result, development of ligands selective for either subtype is a challenging task.
- Parkinson’s disease is a progressive, neurodegenerative disorder that results from the death of DA-producmg cells in the substantia nigra region of the midbrain.
- Common symptoms include resting tremor, muscular rigidity, bradykinesia, postural instability, and cognitive psychiatric complications.
- oxidative stress and mitochondrial dysfunction are thought to play a central role in the pathology of the disease.
- Oxidative stress has been strongly implicated in midbrain dopaminergic cell death.
- a-syrmciein a presynaptic protein involved in fibril lization, has been implicated in the pathogenesis of PD.
- an interaction between calcium, cytosolic DA, and a-synuclein has been implicated in the loss of DA neurons in the substantia nigra.
- DAdependent neurotoxicity is mediated by a soluble protein complex containing a-synuclein, Therefore, a-synuclein, together with oxidized DA, could have synergistic effects in terms of disease susceptibility an progression.
- the present: invention solves one or more problems of the prior art by providing a compound having formula ⁇ for treating a neurodegenerative disease:
- R] is H, Ci-s alkyl, C 2 -s alkenyl, C 4 -s cydoaikyl, CU-s cycioalkenyi, Ce-io aryl, Ci -to alky!
- R 2 , R J , R 4 , Rs are each independently H or OH wherein at least 2 of R 2 , R 3 , R 4 , Rs are OH;
- Re is an optionally substituted Ci-s alkyl, Ci-s alkoxyl, C 2 -s alkenyl, C 2-8 alkynyl, Ci-s
- R ? is an optionally substituted Ci-s alkyl. Cos alkoxyl, C 2-3 alkenyl, C 2-8 alkynyl. Ci-s cydoaikyl, Ci-s cydoalkenyi, or C 0-10 aryl;
- R are each independently hydroxyl, CM alkyl, C alkoxyl. C alkyl, C 2-8 alkenyl. C 2-8 alkynyl, Ci-s cydoaikyl, Ci-s cycloalkenyl; C MO aryl, ⁇ NR or Cwo hydrocarbon groups optionally containing one or more G, N, S, or Se heteroatoms where R’ individually are H or organ yi groups (e,g., C alkyl, Cz-s alkenyl, C 2 -s alkynyl, Ci-s cydoaikyl, Ci-s cycloalkenyl, or Ce-io aryl) and q is 2 or 3. with the proviso that when q is 3, the group bears a positive formal charge (with an appropriate counter ion (e.g,, halide) being present);
- Z m is absent or a divalent linking moiety in which Z is repeated m times;
- 0 is 0, 1, 2, 3, or 4;
- a compound having formula P for treating a neurodegenerative disease is provided:
- A is an optionally substituted CV12 aryl or Ce-i2 heteroaryl
- R)4, R15 are each independently H, Ci-s alkyl, Ci-s alkyl, C2-8 alkenyl, C -8 eycloaikyi, C s cycloalkenyl, Ce-10 aryl, or Ci-io alkyl, or Ce-to aryl;
- o 0, 1 , 2. 3, or 4;
- Ru is an optional substituent.
- FIGURE 1 Synthetic Scheme 1 for compounds that are useful for treating a neurodegenerati ve disease.
- FIGURES 2A-B (A) Inhibition of aSN fibriliizaiion by D-687 and D-688 The drugs were incubated with aSN over a period of six days and the fibrilizaiioti was measured by ThT fluorescence assay. Data Values shown are means ⁇ SEMs of three independent experiments. (B) PCI 2 cells were treated w ith 10 mM prefabricated aSN aggregates formed in presence of daigs collected at day 0 and day 6. Values shown are means ⁇ SEMs of three independent experiments performed in 4-6 replicates. One way ANOVA analysis followed by Tukey's Multiple Comparison post hoc test were performed. (*p ⁇ 0,01 compared to the control),
- FIGURES 3 A and 38 Inhibition and dissociation of Abi-42 oligomer formation by : a) ThT fluorescence of Abi-4 (IOmM ) with or without incubation w ith test compounds (20mM) for 24 h. The ThT fluorescence of Abi-42 at Oh was taken as 100%. b) Abi-42 fibrils ( ⁇ OmM) w'ere incubated with test compounds (20mM) for a period of 24h. The ThT fluorescence of Abi- « aggregates at Oh was considered as 100%
- FIGURE 4 Synthetic Scheme 2 for compounds that are useful for treating a neurodegenerative disease
- FIGURE 5 Synthetic Scheme 3 for compounds that are useful for treating a neurodegenerative disease.
- FIGURE 6 Synthetic Scheme 4 for compounds that are useful for treating a neurodegenerati ve disease.
- R where i is an integer) include hydrogen, alkyl, lower alkyl, C alkyl, CVJO aryl, CV K > heteroaryl, -N ⁇ 1 ⁇ 4, -NH>, -N(R’R”), -N(R’R M R M, ) ⁇ L-, Cl, F, Br, -CFj, -CCb, -CN, - SO H, -PO 3 H 2 , -COOH, -COsR’, -CORE -CBO, -OH, -OR’, -0/NG, -SOyAT, -POyM ⁇ -COO NT, - CF 2 H, -CFiRk -CF3 ⁇ 4, and -CFR’R” where R R” and R”’ are Ci-io alkyl or Ce-is aryl groups (it should he appreciated that these groups can be in addition to other groups listed for a specific R groiup); single letters (e.g., "n
- the integer range 1 -10 explicitly includes 1 , 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- the range 1 to 100 includes 1, 2, 3, 4. . , 97, 98, 99, 100
- intervening numbers that are increments of fee difference between the upper limit an the lower limit divided by 10 can be taken as alternative upper or lower limits, For example, if the range is 1.1. to 2.1 the following numbers 1.2, 1.3, 1 4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 can be selected as lower or upper limits.
- concentrations, temperature, and reaction conditions e.g.
- concentrations, temperature, and reaction conditions e.g., pressure, pH, etc.
- concentrations, temperature, and reactio conditions e.g., pH, etc.
- concentrations, temperature, and reactio conditions can be practiced with pins or minus 10 percent of the values indicated rounded to three significant figures of the value provided in the examples.
- concentrations, temperature, and reaction conditions e.g,, pressure, pH, flow rates, etc.
- concentrations, temperature, and reaction conditions can be practiced with plus or minus 50 percent of the values indicated rounded to or truncated to two significant figures of the value provide in the examples
- concentrations, temperature, and reaction conditions e.g, pressure, pH, How rates, etc.
- concentrations, temperature, and reaction conditions can be practiced with plus or minus 30 percent of the values indicate rounded to or truncated to two significant figures of the value provided in the examples.
- concentrations, temperature, and reaction conditions e.g., pressure, pH, flow rates, etc.
- concentrations, temperature, and reaction conditions can be practiced with plus or minus 10 percent of the values indicated rounded to or truncated to two significant figures of the value provided in the examples,
- organyl group means any organic substituent group, regardless of functional type, having one free valence at a carbon atom.
- organyl group include but are not limited to Ci-s alkyl, C2-8 alkenyl, C2-8 alkynyi, C4-8 cycloalkyl, C4-8 cycloalkenyl, G no aryl, C2-10 aikanediyl, Ci-s alkoxy, Cue thioalkoxy, Cs-is cylcoalkyl, and the like. More specific examples Inc hides, but are not limited to methyl, ethyl, propyl, butyl, pyridinyi , 4-pyridylmeihyl, and the like,
- alkyl means a straight or branched hydrocarbon radical having from 1 to 10 carbon atoms and includes, for example, methyl, ethyl, n -propyl, isopropyl, n-butyi, sec-butyl, isobutyl, tert-butyl, n-pentyl, n ⁇ hexy1, n-heptyl, n-octyl, and the like.
- alkanediyl means a straight or branched hydrocarbo diradical having from 1 to 10 carbon atoms formed by removing 2 hydrogen atoms from an alkane
- the term“alkoxy” and “thioalkoxy” are 0-alkyl or S-alkyl of fro 1 to 8 carbon atoms as defined above for "alkyl”.
- the term“eycloaSkyi” means a saturated hydrocarbon ring having 3 to 8 carbon atoms and includes, for example, cyclopropyl, eyclobutyl, cyelopentyl, cyclohexyl, cycloheptyl, cyclooctyl , and the like.
- alkenyl means a straight or branched unsaturated hydrocarbon radical having from 2 to 12 carbon atoms and includes, for example, ethenyl, 2-propenyl, 1 -bnteny!, 2-butenyl, l-pcntenyl, 2-pen Lenyl, 3-rnethyl-3-butenyl, 1-hexenyi, 2 ⁇ hexenyi, 3-hcxcnyS, 3-heptenyl,
- alkenediyi means a straight or branched hydrocarbon diradical having from 2 to 12 carbon atoms formed by removing 2 hydrogen atoms from a €2-12 alkene.
- alkynyl means straight or branched triple bonded unsaturated hydrocarbon radical having from 2 to 12 carbon atoms and includes, for example, ethynyl, 2- propynyl, 3 ⁇ butynyl, 4-penlynyl, 5-hexynyl, 6-hcptynyl, 7-octynyl, 8-nonynyi, 9-decynyl, 10- undecynyl, l l-dodecynyl, and the like.
- alkynediyl means a straight or branched hydrocarbon diradical having from 2 to 12 carbon atoms formed by removing 2 hydrogen atoms fro a €2-12 alkyne.
- the term“cycloalkyla!ky!” means a saturated hydrocarbon ring attached to an alkyl group wherein alkyl is as defined above.
- the saturated hydrocarbon ring contains from 3 to 12 carbon atoms. Examples of such are cyclopropylmethyi, cyclopentylmetbyl, cyciohexylmethyl, adamantylmethyl and the like.
- heterocycloa!ky means a saturated hydrocarbon ring having 3 to 8 carbon atoms in which 1 or more carbon atoms are replaced by N, S, O, Se, etc. Examples includes
- aryl means an aromatic radical such as a phenyl group, a naphthyl group, a phenyl group substituted by 1 to 4 substituents selected from alkyl as defined above, alkoxy as defined above, ihioalkoxy as defined above, hydroxy, halogen, ieriluoro methyl, amino, a!ky!amino as defined above for alkyl, dia!ky!amino as defined for alkyl, N -acetyl amino, cyano— SO2NH2, or nitro, or a naphthyl group substituted by 1 to 4 substituents as defined above for a phenyl group substituted by 1 to 4 substituents, in a refinement, aryl is a Q.- ai l .
- the term w heteroary!” means a C5-13 heteroaromatic radical such as 2- or 3- thienyl; 2 ⁇ or 3-furanyl; 1 -, 2- or 3-pyrrolyi; 1 ⁇ , 2-, 4 ⁇ , or 5-imidazoIyi; 1 ⁇ , 3-, 4 ⁇ , or 5-pyrazolyS; 2-, 4-, or 5 ⁇ thiazoiyi; 3-, 4-, or S-isothiazol l; 2 ⁇ , 4 ⁇ , or 5-oxazolyS; 3 ⁇ 4-, or 5-isoxazolyl; 1 ⁇ , 3-, or 5-
- heieroaryl is a C5.10 heteroaryl.
- halogen or“halo” means fluorine, chlorine, bromine, or iodine.
- BINAP means 2,2'-bis(diphenylphosphino)-l ,G-binaphthyl
- DMSO dimethylsulfoxide
- DA dopamine
- L-DOPA means (S)-(3,4-dihydroxyphenyI) alanine.
- NaBH(OAc) 3 means sodium triacetoxyborohydride.
- PD Parkinson’s disease
- Pd(OAc)2 means pailadium(II) acetate.
- SCh.py means sulfur trioxide pyridine.
- Ft is room temperature
- TBAF is tetra-ti-buiyiammonium fltoride
- TBS means iert-buty 1 dimethyl si! y 1.
- the present invention provides a compound having formula 1 for treating a neurodegenerative disease:
- Ri is H, C * i 8 alkyl C 2 -8 alkenyl, C 4 -s cycloalkyl C4-& cycloalkenyl, C ⁇ cio aryl, C’w « alkyl
- R 2 , R',, R 4 , Ri are each independently H or OH wherei in a refinement at least 2 of R:>, R 2 , R. 4 , 5 arc Oil
- 3 of R ?. , Rs, R.s, Rs are OH.
- each of (i.e , al! of) Rs, Rj, Ri, R5 are OH;
- R is H, an optionally substituted Ci ⁇ alkyl, an optionally substituted Cue a!koxyl, an optionally substituted C . alkenyl, an optionally substituted C;vs alkynyl, an optionally substituted C 4-8 cycloaikyi, an optionally substituted C 4-8 cycloalkenyl, an optionall substituted Qcio aryl.
- I I R? is H, an optionally substituted C M alkyl, an optionally substituted Cos alkoxyi, an optionally substituted C 2-8 alkenyl, an optionally substituted C 2-8 alkynyl, an optionally substituted C M cycloalkyl, an optionally substituted C 4-8 eycloalkenyi, or an optionally substituted Cs-io aryl;
- Rg are each independently hydroxyl, C M alkyl, C M alkoxyi, C M alkyl, C2-8 alkenyl, C2-8 alkynyl, C M cycloalkyl, CM eycloalkenyi; C MO aryl, -NR 3 q or CM O hydrocarbon groups optionally containing one or more O, N, S, or Se heteroatoms where R 3 individually are H or organ yl groups and q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge; and
- Z m is absent or a divalent linking moiety in which Z is repeated m times;
- o is 0, 1 , 2, 3, or 4 (when o is 0 all substituents are hydrogen (H));and
- n is an integer from 0 to 5.
- R ⁇ ; and R are each independently CM alkyl, C alkenyl, CM alkynyl, CM cycloalkyl, or C eycloalkenyi.
- R ? is substituted with a component selected from the group consisting of halogen, C alkyl, CM alkoxy, CM acyioxy, C M acyl, -C(0)-R3 ⁇ 4 , - Rio-NH-S0 2 -N(R9)r , -Rto-NH- C(C))-Ry; - R;::-N(Ryt. and - Ri -Ar where:
- Ry is H, C alkyl, C M alkenyl, C cycloalkyl, CM cycloalkenyl, or Ce-io aryl;
- r is 2 or 3;
- Ar is a M 0 aryl ring system, optionally including one or more lieteroatoms or Cs-io heteroaryl; with the proviso that when r is 3, the nitrogen of the N(R9) f group will bear a positive formal charge hi a further refinement, Ar is an optionally substituted phenyl, thienyl, pyridy!, bipyridyk biphenylyi, or naphthyl.
- Rs are hydroxyl, C M alkyl, C M alkoxyi, C M alkenyl, C2-8 alkynyl,
- CM eycloalkenyi or C ft -io aryl where q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge and wherein the hydrocarbon groups in each case are optionally substituted with -CN, CM alkyl, -ORu, -OH, halo, or -CF3 ⁇ 4 where R e, is CM alkyl.
- Z can be -CH.>-, -CHOHCH2-, -CHOHCH2CH2-, -CHOHCH2CH2CH2-, -CO-,
- Ci-io carboximido Ci-io alkanediyl, C 2 -io alkanediyl, €2-10 alkynediyl, and combinations thereof; m is 1 , 2, 3, 4, or 5, and n and k are each independently integers 0, 1, 2, 3, 4, 5 ,6, 7, or 8
- a compound having formula P for treating a neurodegenerative disease is provided:
- A is an optionally substituted CM 2 aryl or Ce-i2 heteroaryl
- Ri4 are each independently H, Ci s alkyl, C2-S alkenyl, C 4 -s eycloalkyl, C 4 -s cycloalkenyl, C f t-to aryl, Ci-io alkyl, or CMO and;
- o 0, 1 , 2, 3, or 4;
- R u is an optional substituent as set forth above for example of R group substituents. (0067] in a variation of the compounds having formula 11.
- A is optionally substituted phenyl:
- Ri?, Ris, Riv, R 20 are each independently H, Cos alkyl, OH, or halide (e.g,, F, Ci, Br, 1) or any R group substituent set forth above.
- A is a substituted phenyl having 1, 2, 3, or 4 hydroxyl groups.
- A is:
- R ⁇ . « ⁇ > are H, hydroxyl, halogen, nitro, cyano, Cj-s alkyl, Cue alkoxyl, C 2 - s alkenyl, C2-8 alkynyl, C4-8 cycloalkyl, C4-8 cycloalkenyl; Ce-to aryl, -N(Rn) q -NH-C(0)-Ru, or - NH- €(0)-N(RI2)2, where Rn individually are H, Ci-& alkyl, C2-8 alkenyl, € 2-10 alkynyl, C 4 -8 cycloalkyl, C 4-8 cycloalkenyl, or C- 6 -io aryl where q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge and wherein the hydrocarbon groups in each case are optionally substituted with -CN, Ci-s alkyl, -ORr > , -
- the compounds set forth herein may be used per se or as pharmaceutically accepta derivatives.
- the latter term includes salts, esters, and other derivatives generally considered acceptable by pharmaceutical standards.
- Useful derivatives include salts of organic and inorganic acids such as sulfates, phosphates, hydrohalide salts, carboxylaie salts, etc., as well as esters of carboxylic acid or hydroxyl substituents, ethers of hydroxyl substituents, amides of amino substituents, as well as carbamates, ureas, etc. Synthesis of these derivatives is conventional, and well known to those skilled in pharmaceutical chemistry.
- esters may he converted to esters by customary techniques of organic chemistry, such as reaction with an acyl halide, carboxylic acid anhydride, or by esterification with an acid while removing byproduct water.
- derivation may be desired to facilitate compounding of the pharmaceutical into an acceptable form such as tablets, powder, aqueous dispersion, capsule, etc , or may be useful in assi sting bioavailability of the drug following administration, for example, by rendering the compound more or less soluble.
- esters, ureas such as, for example, esters, ureas
- the derivative may act as“prodrug,” which liberates the active form by biological transformation, i.e. t by enzymatic hydrolysis of an ester functionality, as is well known to the pharmaceutical chemist.
- a method for treating a subject with a neurodegenerative disease in another embodiment, a method for treating a subject with a neurodegenerative disease.
- the method includes a step of identifying a subject having a CMS disease.
- a therapeutic amount of a compound having formula 1 or 11 or any of the variation or refinements thereof is administered to the subject.
- neurodegenerative diseases includes drug addiction, schizophrenia, depression, and Parkinson; s disease (PD).
- PD s disease
- Typical dosages for mammalian subjects may vary from 0.001 mg Kg of body weight to about 100 mg Kg of body weight, preferably 0.01 nig-Kg to 5 mg/Kg Tire actual amount will vary depending upon the particular CNS activity desired to be altered, and the desired degree of alteration. The upper limits may, as with virtually ail drugs, be limited by toxicity of the drug or its metabolites, or by the presence of unwanted side effects.
- the drugs may be administered in any form, but preferably in the form of tablets or capsules with appropriate excipients. Dosages, forms of administration, etc., can be readily determined by those skilled in the art.
- Figure 1 provides a synthetic scheme for compounds having formula I.
- Figure 2 provides (A) inhibition of aSN tibrillization by D-687 and D-688. The drugs were incubated with aSN over a period of six days and the fibrilization was measured by ThT fluorescence assay. Data Values shown are means ⁇ SEMs of three independent experiments, (B) PC 12 cells were treated with 10 mM prefabricated aSN aggregates formed in presence of drugs collected at day 0 and day 6. Values shown are means ⁇ SEMs of three independent experiments performed in 4-6 replicates. One way ANOVA analysis followed by Tukey's Multiple Comparison post hoc test were performed. (*p ⁇ 0.0l compared to the control).
- Figure 3 A and 3B show inhibition and dissociation of Ab oligomer formation by : a) ThT fluorescence of Ab 1-42 (10mM) with or without incubation with test compounds (20mM) for 24 h. The ThT fluorescence of Abi- 2 at Oh was taken as 100%. b) Abi-42 fibrils (10mM) were incubated with test compounds (20mM) for a period of 24h. The ThT fluorescence of Abi-42 aggregates at Oh was considered as 100%
- L4-Bis(chloromethyl)-2,5-dimethoxybenzene (2) Paraformaldehyde (3.3 g, 108,6 mmol) was added to a slurry of compoun 1 (5.0 g, 36,2 mmol) in cone HC1 (15 mL) and acetic acid (15 mL) at rt under inert gas atmosphere. The mixture was sonicated for 2h, Hie mixture was filtered and the solid w3 ⁇ 4s washed with hexane (3 X 50 mL) followed by acetone (15 mL).
- reaction mixture was stirred at 50 °C for !h. Temperature was increased to 85 °C and the reaction mixture was allowed to stir at that temperature for additional 5 minutes. The mixture was cooled to rt. The reaction mixture was diluted with water (100 ml.) and extracted with ethyl acetate (3 X 150 mL). The combined organic layer was washed with water, brine, dried over NajSOi, and solvent was removed under vacuum.
- Reaction temperature was raised to 55 °C and the mixture was stirred for 4 h, Alter cooling, water (1 mL) and concentrated HC1 (2 mL) were added at 0 °C and then THF was evaporated under vacuum. 25% NaOH solution (20 mL) was added to the aqueous phase and extracted with EtOAc (3 x 25 mL). The combined organic layer was dried using NaaSCU, and the solvent was removed under reduced pressure.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A compound having formula I is useful for treating a neurodegenerative disease: (I) or a pharmaceutically acceptable salt or ester thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 are each independently hydroxyl, C1-4 alkyl, C1-4 alkoxyl, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C4-8, are specified substituents.
Description
N EURO PROTECTIVE AGENTS FOR TREATMENT OF NEURO DEGENERATIVE DISEASES
CROSS-REFERENCE TO RELA TED APPLICA TIONS
[0001 I This application is a continuation-in-part of U.S. Serial No 16/124,974 filed September 7,
2018.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] The invention was made with Government support under Contract No. NS047198 awarded by the National Institutes of Health / National institute of Neurological Disorders and Stroke, The Government has certain rights to the invention
TECHNICAL FIELD
[0003[ The present invention relates to compounds for treating neurodegenerative diseases.
BACKGROUND OF THE INVENTION
[0004] Dopaminergic receptor systems have been targeted for the development of pharmaeotherapeulic agents for a number of CNS related disorders, including drug addiction, schizophrenia, depression, and Parkinson’s disease (PD). Dopamine (DA) receptor agonists have been employed more extensively in the treatment of Parkinson’s disease than any other type of pharmacotherapy. Levodopa (L-dopa), the immediate precursor to endogenous DA, is the current gold-standard treatment option for PD. DA receptors belong to the family of transmembrane proteins known as G-protein-coupled receptors (GPCRs). DA receptors are widely distributed in the CNS, are also present in the periphery, and are divided into five subtypes. On the basis of the stimulatory action on adenyiyl cyclase, Dl and D5 are grouped together as Dl type. D2-D4 receptors are classified as D2 type because of their inhibitory action on adeny!yl cyclase activity. Interestingly, the D3 receptor was found to have a distribution in the brain that is somewhat different from that of the D2 receptor. The highest levels of D3 receptor expression were found to be in the limbic region of the brain, while D2 receptor expression is most dense i n the striatum of the midbrain. D2 and D3 receptor subtypes occur post- and presynapiically. In the latter location they function as autoreceptors that regulate DA synthesis, metabolism, and release. It is noteworthy that D2 and D3
I
receptor subtypes share 50% overall amino acid sequence homology and 75-80% in their agonist binding sites. As a result, development of ligands selective for either subtype is a challenging task.
(00051 Parkinson’s disease (PD) is a progressive, neurodegenerative disorder that results from the death of DA-producmg cells in the substantia nigra region of the midbrain. Common symptoms include resting tremor, muscular rigidity, bradykinesia, postural instability, and cognitive psychiatric complications. Although the etiology of PD is not yet clear and may be multi factorial, oxidative stress and mitochondrial dysfunction are thought to play a central role in the pathology of the disease. Recent studies on various genetic mutations have provided new insights into the disease process. Oxidative stress has been strongly implicated in midbrain dopaminergic cell death. Toxicity from endogenous and exogenous origins, caused by oxidative mechanisms, has been implicated as a fundamental process in progressive nigral cell loss. Along with motor fluctuations and wearing off after long-term treatment, side effects associated with L-dopa treatment and the eventual oxidation of DA derived from L-dopa have been speculated to produce further oxidative stress.
|00061 In addition, a-syrmciein, a presynaptic protein involved in fibril lization, has been implicated in the pathogenesis of PD. A recent report demonstrated that in cultured human dopaminergic neurons, accumulation of a-synuclein induces apoptosis in the presence of DA and reactive oxygen species. Furthermore, an interaction between calcium, cytosolic DA, and a-synuclein has been implicated in the loss of DA neurons in the substantia nigra. In this case, DAdependent neurotoxicity is mediated by a soluble protein complex containing a-synuclein, Therefore, a-synuclein, together with oxidized DA, could have synergistic effects in terms of disease susceptibility an progression.
100071 Accordingly, there is a need for dopamine improved D2/D3 agonist molecules, and in particular, for improved D2/D3 agonist molecules with a capacity to bind to iron.
7
SUMMARY OF THE INVENTION jjOOGSj In at least one embodiment, the present: invention solves one or more problems of the prior art by providing a compound having formula Ϊ for treating a neurodegenerative disease:
R] is H, Ci-s alkyl, C2-s alkenyl, C4-s cydoaikyl, CU-s cycioalkenyi, Ce-io aryl, Ci -to alky!
R2, RJ, R4, Rs are each independently H or OH wherein at least 2 of R2, R3, R4, Rs are OH;
Re is an optionally substituted Ci-s alkyl, Ci-s alkoxyl, C2-s alkenyl, C2-8 alkynyl, Ci-s
R? is an optionally substituted Ci-s alkyl. Cos alkoxyl, C2-3 alkenyl, C2-8 alkynyl. Ci-s cydoaikyl, Ci-s cydoalkenyi, or C0-10 aryl;
Rs are each independently hydroxyl, CM alkyl, C alkoxyl. C alkyl, C2-8 alkenyl. C2-8 alkynyl, Ci-s cydoaikyl, Ci-s cycloalkenyl; CMO aryl, ~NR or Cwo hydrocarbon groups optionally containing one or more G, N, S, or Se heteroatoms where R’ individually are H or organ yi groups (e,g., C alkyl, Cz-s alkenyl, C2-s alkynyl, Ci-s cydoaikyl, Ci-s cycloalkenyl, or Ce-io aryl) and q is
2 or 3. with the proviso that when q is 3, the group bears a positive formal charge (with an appropriate counter ion (e.g,, halide) being present);
Zm is absent or a divalent linking moiety in which Z is repeated m times;
0 is 0, 1, 2, 3, or 4; and
is 0, 1 , 2, 3, 4, or 5. In another embodiment, a compound having formula P for treating a neurodegenerative disease is provided:
wherein:
A is an optionally substituted CV12 aryl or Ce-i2 heteroaryl;
R)4, R15 are each independently H, Ci-s alkyl, Ci-s alkyl, C2-8 alkenyl, C -8 eycloaikyi, C s cycloalkenyl, Ce-10 aryl, or Ci-io alkyl, or Ce-to aryl;
B j and B;> are each independently:
Ru, is an optional substituent.
BRIEF DESCRIPTIO OF THE DRA WINGS
JjOOiOj Exemplary embodiments of the present invention will become more fully understood from the detailed description and the accompanying drawings, wherein:
[00111 FIGURE 1. Synthetic Scheme 1 for compounds that are useful for treating a neurodegenerati ve disease.
[0012j FIGURES 2A-B. (A) Inhibition of aSN fibriliizaiion by D-687 and D-688 The drugs were incubated with aSN over a period of six days and the fibrilizaiioti was measured by ThT fluorescence assay. Data Values shown are means ± SEMs of three independent experiments. (B) PCI 2 cells were treated w ith 10 mM prefabricated aSN aggregates formed in presence of daigs collected at day 0 and day 6. Values shown are means ± SEMs of three independent experiments performed in 4-6 replicates. One way ANOVA analysis followed by Tukey's Multiple Comparison post hoc test were performed. (*p<0,01 compared to the control),
[0013J FIGURES 3 A and 38. Inhibition and dissociation of Abi-42 oligomer formation by : a) ThT fluorescence of Abi-4 (IOmM ) with or without incubation w ith test compounds (20mM) for 24 h. The ThT fluorescence of Abi-42 at Oh was taken as 100%. b) Abi-42 fibrils (ΊOmM) w'ere incubated with test compounds (20mM) for a period of 24h. The ThT fluorescence of Abi-« aggregates at Oh was considered as 100%
10014] FIGURE 4, Synthetic Scheme 2 for compounds that are useful for treating a neurodegenerative disease
[0015] FIGURE 5. Synthetic Scheme 3 for compounds that are useful for treating a neurodegenerative disease.
[00I6[ FIGURE 6. Synthetic Scheme 4 for compounds that are useful for treating a neurodegenerati ve disease.
DETAILED DESCRIPTION OF THE INVENTION
[00I7{ Reference will now' be made in detail to presently preferred compositions, embodiments and methods of the present invention, which constitute the best modes of practicing the invention presently known to the inventors. The Figures are not necessarily to scale. However, it is to be
understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various and alternative forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for any aspect of the invention and or as a representative basis for teaching one skilled in the art to variously employ the present invention.
Except in the examples, or where otherwise expressly indicated, all numerical quantities in this description indicating amounts of material or conditions of reaction and/or use are to be understood as modified by the word "about" in describing the broadest scope of the invention. Practice within the numerical limits stated is generally preferred. Also, unless expressly stated to the contrary: all R groups (e.g. R where i is an integer) include hydrogen, alkyl, lower alkyl, C alkyl, CVJO aryl, CVK> heteroaryl, -N<¼, -NH>, -N(R’R”), -N(R’RMRM,)÷L-, Cl, F, Br, -CFj, -CCb, -CN, - SO H, -PO3H2, -COOH, -COsR’, -CORE -CBO, -OH, -OR’, -0/NG, -SOyAT, -POyM \ -COO NT, - CF2H, -CFiRk -CF¾, and -CFR’R” where R R” and R”’ are Ci-io alkyl or Ce-is aryl groups (it should he appreciated that these groups can be in addition to other groups listed for a specific R groiup); single letters (e.g., "n" or "o" l are 1 , 2, 3, 4, or 5; in the compounds disclosed herein a CH bond can be substituted with alkyl, lower alkyl, C alkyl, CVJO aryl, Ce-io heteroaryl, -NO2, -N¾ - M(R/ R”), -N(R,R”R,,,)l·, Cl, F, Br, -CFj, -OCR, -CN, -SO3H, -PO3H3, -COOH, -C(½R’, -COR/, - CHO, -OH, -OR/, -0 M+, -SOkMy -POs M , -COCrNT, -CF2H, -CFhR’, ~CFH2, and -CFR’R” where R’, R” and R’” are Ci-10 alkyl or Ce-is aryl groups; percent, "parts of," and ratio values are by weight; the term "polymer" includes "oligomer," "copolymer," "terpolymer," and the like; molecular weights provided for any polymers refers to weight average molecular weight unless otherwise indicated; the description of a group or class of materials as suitable or preferred for a given purpose in connection with the invention implies that mixtures of any two or more of the members of the group or class are equally suitable or preferred; description of constituents in chemical terms refers to he constituents at the time of addition to any combination specified in the description, and does not necessarily preclude chemical interactions among the constituents of a mixture once mixed; the first definition of an acronym or other abbreviation applies to ail subsequent uses herein of the same abbreviation and applies mutatis mutandis to normal grammatical variations of the initially defined abbreviation; and, unless expressly stated to the contrary, measurement of a property is determined by the same technique as previously or later referenced for the same property. It is also to be understood that this invention is not limited to the specific embodiments and methods described below, as specific component and/or conditions may, of course, vary.
Furthermore, the terminology used herein is used only for the purpose of describing particular embodiments of the present invention and is not intended to be limiting in any way.
[0020) it must also be note that, as used in the specification and the appended claims, the singular for "a," "an*" and "the" comprise plural referents unless the context clearly indicates otherwise. For example, reference to a component in the singular is intended to comprise a plurality of components.
[0021) The term “comprising” is synonymous with “including,” “having,” “containing,” or
“characterized by.” These terms are inclusive an open-ended and do not exclude additional, unrecited elements or method steps.
[0022) The phrase“consisting of’ excludes any element, step, or ingredient not specified in the claim. When this phrase appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth i that clause; other elements are not excluded from the claim as a whole.
[0023] The phrase“consisting essentially of’ limits the scope of a claim to the specified materials or steps, plus those that do not materially affect the basic and novel characteristic^) of the claimed subject matter
[0024) With respect to the terms“comprising,”“consisting of,” and“consisting essentially of,” where one of these three terms is used herein, the presently disclosed and claimed subject matter can incl ude the use of ei ther of the other t O terms.
J0025) It should also be appreciated that integer ranges explicitly include all intervening integers.
For example, the integer range 1 -10 explicitly includes 1 , 2, 3, 4, 5, 6, 7, 8, 9, and 10. Similarly, the range 1 to 100 includes 1, 2, 3, 4. . , 97, 98, 99, 100 Similarly, when any range is calle for, intervening numbers that are increments of fee difference between the upper limit an the lower limit divided by 10 can be taken as alternative upper or lower limits, For example, if the range is 1.1. to 2.1 the following numbers 1.2, 1.3, 1 4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 can be selected as lower or upper limits. In the specific examples set forth herein, concentrations, temperature, and reaction conditions (e.g. pressure, pH, etc.) can be practiced with plus or minus 50 percent of the values indicated rounded to three significant figures, in a refinement, concentrations, temperature, and reaction conditions (e.g., pressure, pH, etc.) can be practiced with plus or minus 30 percent of the values indicated rounded to three significant figures of fee value provided in the examples. In
another refinement, concentrations, temperature, and reactio conditions (e.g., pH, etc.) can be practiced with pins or minus 10 percent of the values indicated rounded to three significant figures of the value provided in the examples.
[0026] in the examples set forth herein, concentrations, temperature, and reaction conditions (e.g,, pressure, pH, flow rates, etc.) can be practiced with plus or minus 50 percent of the values indicated rounded to or truncated to two significant figures of the value provide in the examples, hi a refinement, concentrations, temperature, and reaction conditions (e.g,, pressure, pH, How rates, etc.) can be practiced with plus or minus 30 percent of the values indicate rounded to or truncated to two significant figures of the value provided in the examples. In another refinement, concentrations, temperature, and reaction conditions (e.g., pressure, pH, flow rates, etc.) can be practiced with plus or minus 10 percent of the values indicated rounded to or truncated to two significant figures of the value provided in the examples,
[00271 Throughout this application, where publications are referenced, the disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which thi invention pertains,
[0028] In a variation, the term“organyl group” means any organic substituent group, regardless of functional type, having one free valence at a carbon atom. Examples of organyl group include but are not limited to Ci-s alkyl, C2-8 alkenyl, C2-8 alkynyi, C4-8 cycloalkyl, C4-8 cycloalkenyl, G no aryl, C2-10 aikanediyl, Ci-s alkoxy, Cue thioalkoxy, Cs-is cylcoalkyl, and the like. More specific examples Inc hides, but are not limited to methyl, ethyl, propyl, butyl, pyridinyi , 4-pyridylmeihyl, and the like,
[0029] in a variation, the term“alkyl” means a straight or branched hydrocarbon radical having from 1 to 10 carbon atoms and includes, for example, methyl, ethyl, n -propyl, isopropyl, n-butyi, sec-butyl, isobutyl, tert-butyl, n-pentyl, n~hexy1, n-heptyl, n-octyl, and the like.
[O030J In a variation, the term“aikanediyl” means a straight or branched hydrocarbo diradical having from 1 to 10 carbon atoms formed by removing 2 hydrogen atoms from an alkane,
[O031J In a variation, the term“alkoxy” and "thioalkoxy" are 0-alkyl or S-alkyl of fro 1 to 8 carbon atoms as defined above for "alkyl".
[0032] In a variation, the term“eycloaSkyi” means a saturated hydrocarbon ring having 3 to 8 carbon atoms and includes, for example, cyclopropyl, eyclobutyl, cyelopentyl, cyclohexyl, cycloheptyl, cyclooctyl , and the like.
{00331 In a variation, the term“alkenyl” means a straight or branched unsaturated hydrocarbon radical having from 2 to 12 carbon atoms and includes, for example, ethenyl, 2-propenyl, 1 -bnteny!, 2-butenyl, l-pcntenyl, 2-pen Lenyl, 3-rnethyl-3-butenyl, 1-hexenyi, 2~hexenyi, 3-hcxcnyS, 3-heptenyl,
1-ocienyl, l-nonenyl, l -decenyi, l-undecenyi, l-dodecenyl, and the like
10034] In a variation, the term“alkenediyi” means a straight or branched hydrocarbon diradical having from 2 to 12 carbon atoms formed by removing 2 hydrogen atoms from a€2-12 alkene.
10035] in a variation, the term“alkynyl” means straight or branched triple bonded unsaturated hydrocarbon radical having from 2 to 12 carbon atoms and includes, for example, ethynyl, 2- propynyl, 3~butynyl, 4-penlynyl, 5-hexynyl, 6-hcptynyl, 7-octynyl, 8-nonynyi, 9-decynyl, 10- undecynyl, l l-dodecynyl, and the like.
[0036] In a variation, the term“alkynediyl” means a straight or branched hydrocarbon diradical having from 2 to 12 carbon atoms formed by removing 2 hydrogen atoms fro a€2-12 alkyne.
[0037] In a variation, the term“cycloalkyla!ky!” means a saturated hydrocarbon ring attached to an alkyl group wherein alkyl is as defined above. The saturated hydrocarbon ring contains from 3 to 12 carbon atoms. Examples of such are cyclopropylmethyi, cyclopentylmetbyl, cyciohexylmethyl, adamantylmethyl and the like.
[0038] In a variation, the term“heterocycloa!ky!” means a saturated hydrocarbon ring having 3 to 8 carbon atoms in which 1 or more carbon atoms are replaced by N, S, O, Se, etc. Examples includes
2- or 3 -tetrah drothieno, 2- or 3-tetrahydrofurano, 2- or 3-pyrroIidino, 2-, 4-, or 5-thiazolidino, 2-, 4- , or 5~oxazolidino, 2~, 3-, or 4-piperidino, N-morpholinyl or N-thiamorpholin l,
[0039] In a variation, the term“aryl” means an aromatic radical such as a phenyl group, a naphthyl group, a phenyl group substituted by 1 to 4 substituents selected from alkyl as defined above, alkoxy as defined above, ihioalkoxy as defined above, hydroxy, halogen, iriiluoro methyl, amino, a!ky!amino as defined above for alkyl, dia!ky!amino as defined for alkyl, N -acetyl amino, cyano—
SO2NH2, or nitro, or a naphthyl group substituted by 1 to 4 substituents as defined above for a phenyl group substituted by 1 to 4 substituents, in a refinement, aryl is a Q.- ai l .
|0040) in a variation, the term wheteroary!” means a C5-13 heteroaromatic radical such as 2- or 3- thienyl; 2~ or 3-furanyl; 1 -, 2- or 3-pyrrolyi; 1 ~, 2-, 4~, or 5-imidazoIyi; 1 ~, 3-, 4~, or 5-pyrazolyS; 2-, 4-, or 5~thiazoiyi; 3-, 4-, or S-isothiazol l; 2~, 4~, or 5-oxazolyS; 3~ 4-, or 5-isoxazolyl; 1~, 3-, or 5-
1.2.4-iriazolyl; 1-, 2-, 4-, or 5-l ,2,3-triazoly1; - or 5~tetrazolyl; 4-, or 5-l ,2,3~oxadiazoly1; 3-, or 5-
1.2.4-oxadiazolyl; 2-1 ,3,4-oxadiazolyl; 2-l ,3,4~thiadiazoyl; 2~i,3,5-iriazinyl; 3-pyridinyI; 3~, 4~„ or 5~pyridazinyl; 2-pyrazinyl; 2~, 4-, or 5-pyrimidinyl; unsubstituted or substituted by 1 to 2 substituents selected from NH?, OH, S, halogen as defined hereinafter, alkyl as defined above, or alkoxy as defined above. In a refinement, heieroaryl is a C5.10 heteroaryl.
[0041] In a variation, the term“halogen” or“halo” means fluorine, chlorine, bromine, or iodine.
[0042] Abbreviations;
[0043] “BINAP” means 2,2'-bis(diphenylphosphino)-l ,G-binaphthyl
[0044] “DMSO” is dimethylsulfoxide;
[0045] “DA” means dopamine.
[0046] “et” is ethyl;
[0047] “me” is methyl ;
[0048] “h” is hour;
[0049] “L-DOPA” means (S)-(3,4-dihydroxyphenyI) alanine.
[0050] “NaBH(OAc)3” means sodium triacetoxyborohydride.
[0051] “PD: Parkinson’s disease.
[0052] “Pd(OAc)2” means pailadium(II) acetate.
[0053] “s” i: s seconds;
[0054] “SCh.py” means sulfur trioxide pyridine.
[0055] “ft” is room temperature;
[0056] TBAF” is tetra-ti-buiyiammonium fltoride;
|0057| “THF” is tetrahydrofuran;
[0058] “TBS” means iert-buty 1 dimethyl si! y 1.
[0059] In at least one embodiment, the present invention provides a compound having formula 1 for treating a neurodegenerative disease:
wherein:
Ri is H, C*i 8 alkyl C2-8 alkenyl, C4-s cycloalkyl C4-& cycloalkenyl, C<cio aryl, C’w« alkyl
R2, R',, R4, Ri are each independently H or OH wherei in a refinement at least 2 of R:>, R2, R.4, 5 arc Oil In another refinement, 3 of R?., Rs, R.s, Rs are OH. In still another refinement, each of (i.e , al! of) Rs, Rj, Ri, R5 are OH;
R , is H, an optionally substituted Ci^ alkyl, an optionally substituted Cue a!koxyl, an optionally substituted C . alkenyl, an optionally substituted C;vs alkynyl, an optionally substituted C4-8 cycloaikyi, an optionally substituted C4-8 cycloalkenyl, an optionall substituted Qcio aryl.
I I
R? is H, an optionally substituted CM alkyl, an optionally substituted Cos alkoxyi, an optionally substituted C2-8 alkenyl, an optionally substituted C2-8 alkynyl, an optionally substituted CM cycloalkyl, an optional ly substituted C4-8 eycloalkenyi, or an optionally substituted Cs-io aryl;
Rg are each independently hydroxyl, CM alkyl, CM alkoxyi, CM alkyl, C2-8 alkenyl, C2-8 alkynyl, CM cycloalkyl, CM eycloalkenyi; CMO aryl, -NR3 q or CMO hydrocarbon groups optionally containing one or more O, N, S, or Se heteroatoms where R3 individually are H or organ yl groups and q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge; and
Zm is absent or a divalent linking moiety in which Z is repeated m times;
o is 0, 1 , 2, 3, or 4 (when o is 0 all substituents are hydrogen (H));and
m is an integer from 0 to 5. In a refinement, the compound of claim 1 wherein R{; and R are each independently CM alkyl, C alkenyl, CM alkynyl, CM cycloalkyl, or C eycloalkenyi.
10060} In a refinement, R? is substituted with a component selected from the group consisting of halogen, C alkyl, CM alkoxy, CM acyioxy, CM acyl, -C(0)-R¾ , - Rio-NH-S02-N(R9)r , -Rto-NH- C(C))-Ry; - R;::-N(Ryt. and - Ri -Ar where:
Ry is H, C alkyl, CM alkenyl, C cycloalkyl, CM cycloalkenyl, or Ce-io aryl;
Rio is C alkenyl;
r is 2 or 3; and
Ar is a M 0 aryl ring system, optionally including one or more lieteroatoms or Cs-io heteroaryl; with the proviso that when r is 3, the nitrogen of the N(R9)f group will bear a positive formal charge hi a further refinement, Ar is an optionally substituted phenyl, thienyl, pyridy!, bipyridyk biphenylyi, or naphthyl.
|0061} In another refinement, Rs are hydroxyl, CM alkyl, CM alkoxyi, CM alkenyl, C2-8 alkynyl,
C4-8 cycloalkyl, CM eycloalkenyi; CMO aryl, -N(Rn)¾ ~NH-C(0)~Rn, or -NH-C(0)-N(RI2)2, where Ru individually are H, CM alkyl, C2.8 alkenyl, C>-io alkynyl, CM cycloalkyl. CM eycloalkenyi, or Cft-io aryl where q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge and wherein the hydrocarbon groups in each case are optionally substituted with -CN, CM alkyl, -ORu, -OH, halo, or -CF¾ where R e, is CM alkyl.
10062] When present, Z can be -CH.>-, -CHOHCH2-, -CHOHCH2CH2-, -CHOHCH2CH2CH2-, -CO-,
-N-CH2-, -N-CO-, -(Clh - , -CHOH(CHi)u-, -(Ok^CO-, -(CHS^NCOCCHJ » Ci-io carboximido,
Ci-io alkanediyl, C2-io alkanediyl,€2-10 alkynediyl, and combinations thereof; m is 1 , 2, 3, 4, or 5, and n and k are each independently integers 0, 1, 2, 3, 4, 5 ,6, 7, or 8
|0063l in a variation, more specific compounds having formula 1 are provided by the following formula:
In another variation, more specific compounds having formula I are provided by the following formula:
and pharmaceutically acceptable salts and esters thereof,
J0065] Specific useful compounds having formula Ϊ are the following compounds:
13c (D-688) ; and pharmaceutically acceptable salts and esters thereof.
100661 In another embodiment, a compound having formula P for treating a neurodegenerative disease is provided:
wherein:
A is an optionally substituted CM 2 aryl or Ce-i2 heteroaryl;
Ri4, Ris are each independently H, Ci s alkyl, C2-S alkenyl, C4-s eycloalkyl, C4-s cycloalkenyl, Cft-to aryl, Ci-io alkyl, or CMO and;
B j and B;> are each independently
R u, is an optional substituent as set forth above for example of R group substituents.
(0067] in a variation of the compounds having formula 11. A is optionally substituted phenyl:
where Ri?, Ris, Riv, R20 are each independently H, Cos alkyl, OH, or halide (e.g,, F, Ci, Br, 1) or any R group substituent set forth above. In a refinement, A is a substituted phenyl having 1, 2, 3, or 4 hydroxyl groups. In a further refinement, A is:
|0068) In another variation, more specific compounds having formula 11 are provided by the following formula:
10069] In another refinement, R ·.«·> are H, hydroxyl, halogen, nitro, cyano, Cj-s alkyl, Cue alkoxyl, C2- s alkenyl, C2-8 alkynyl, C4-8 cycloalkyl, C4-8 cycloalkenyl; Ce-to aryl, -N(Rn)q -NH-C(0)-Ru, or - NH-€(0)-N(RI2)2, where Rn individually are H, Ci-& alkyl, C2-8 alkenyl, €2-10 alkynyl, C4-8 cycloalkyl, C4-8 cycloalkenyl, or C-6-io aryl where q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge and wherein the hydrocarbon groups in each case are optionally substituted with -CN, Ci-s alkyl, -ORr>, -OH, halo, or -CF3 where R is Cos alkyl.
100701 The compounds set forth herein may be used per se or as pharmaceutically accepta derivatives. The latter term includes salts, esters, and other derivatives generally considered acceptable by pharmaceutical standards. Useful derivatives, for example, include salts of organic and inorganic acids such as sulfates, phosphates, hydrohalide salts, carboxylaie salts, etc., as well as esters of carboxylic acid or hydroxyl substituents, ethers of hydroxyl substituents, amides of amino substituents, as well as carbamates, ureas, etc. Synthesis of these derivatives is conventional, and well known to those skilled in pharmaceutical chemistry. For example, compounds bearing hydroxyl groups may he converted to esters by customary techniques of organic chemistry, such as reaction with an acyl halide, carboxylic acid anhydride, or by esterification with an acid while removing byproduct water. In some cases, derivation may be desired to facilitate compounding of the pharmaceutical into an acceptable form such as tablets, powder, aqueous dispersion, capsule, etc , or may be useful in assi sting bioavailability of the drug following administration, for example, by rendering the compound more or less soluble. In many cases, such as, for example, esters, ureas,
I B
carbamates, ethers, etc., the derivative may act as“prodrug,” which liberates the active form by biological transformation, i.e.t by enzymatic hydrolysis of an ester functionality, as is well known to the pharmaceutical chemist.
10071] In another embodiment, a method for treating a subject with a neurodegenerative disease.
The method includes a step of identifying a subject having a CMS disease. A therapeutic amount of a compound having formula 1 or 11 or any of the variation or refinements thereof is administered to the subject. Examples of such neurodegenerative diseases includes drug addiction, schizophrenia, depression, and Parkinson; s disease (PD). Typical dosages for mammalian subjects may vary from 0.001 mg Kg of body weight to about 100 mg Kg of body weight, preferably 0.01 nig-Kg to 5 mg/Kg Tire actual amount will vary depending upon the particular CNS activity desired to be altered, and the desired degree of alteration. The upper limits may, as with virtually ail drugs, be limited by toxicity of the drug or its metabolites, or by the presence of unwanted side effects. The drugs may be administered in any form, but preferably in the form of tablets or capsules with appropriate excipients. Dosages, forms of administration, etc., can be readily determined by those skilled in the art.
10072] Guidelines to the effective dosages in mammalian species are provided by the many known drugs commercially available which bind to CNS monoamine receptor sites, and by comparing the binding affinities of these pharmaceuticals with the target compounds of the subject invention by in vivo and in vitro studies, in addition to the utility of the subject invention compounds in treatment of diseases such as Parkinson's disease, schizophrenia, treatment for addiction such as cocaine addiction, and the like, die subject invention compounds are also useful, particularly in their radio labeled form, for clinical studies directed to distribution of monoamine receptor sites in the brain and the effect which compounds, such as cocaine, have on these sites.
100731 The following examples illustrate the various embodiments of the present invention, Those skilled i the art will recognize many variations that are within the spirit of the present invention and scope of the claims.
10074] Figure 1 provides a synthetic scheme for compounds having formula I.
10075] I, Scheme 1 (Figure 1)
10076] 1. ( 2- B r om o- e tho \ yHert-b u ty 1 -dime thy 1- silane
|0077| A solution of bromoethanol 1 (1 mL, 14.1 mmol), imidazole (1.9 g, 27,9 mmol), and tert- butyldimetbyisilyl chloride (2.1 g, 13,9 mmol) in CH2CI2 (15 mL) was stirred at room temperature for 20 h. Alter the reaction was complete, water (20 mL) was added, and reaction mixture was extracted with CH2CI2 (3 x 50 mL), The CH2CI2 layer was dried over NaiSCL, filtered, and concentrated in vacuo. The resulting crude was purified by column chromatography using 5% ethyl acetate in hexanes to give compound 2 (2,85 g, 86%). 5H NMR (CDCL, 600 MHz): S ppm 0,09 (s, 6H), 0,91 (s, 9H), 3,40 (t, J = 6,6 Hz, 2H), 3.89 (t, J = 6,6 Hz, 2H).
100781 2. l- 2-(tert-Biityl-dimethyl-silanylox:y)-ethylj-piperazine
100791 A suspension of piperazine 3 (2.3 g, 26.7 tnmo!), intermediate 2 (2.55 g, 10.7 mmol), and potassium carbonate (11 g, 79,6 mmol) in acetonitrile (35 mL) was refluxed at 80-90 °C for overnight. The reaction mixture was filtered, and the filtrate was condensed in vacuo. The residue was then diluted with ether, washed with water, dried over Na^SCM, filtered, and concentrated to produce intermediate 4 (2.19 g, 84%). !H NMR (CDClj, 600 MHz): d ppm 0.06 (s, 6H), 0.89 (s, 9H), 2.49-2.53 (m, 6H), 2.89 (t, J - 4.8 Hz, 4M h 3.76 (t, J ~ 6.6 Hz, 2H).
|0080{ 3. 4t-bromo-3,4-dimethoxy-l,l '-biphenyl
100811 Into a mixture of starting material 5 (5.96 g, 25.3 mmol), Pd(PPhO-s (0.73 g, 0.63 mmol), and
K2CCK (3,5 g, 25.3 mmol) in ioluene/HsO (20 mL, 10 mL), a suspension of boronic acid 6 (2.3 g, 12,6 mmol) in ethanol (10 mL) was added and stirred at room temperature for 10 min. The reaction mixture was refluxed at 85-90 °C for 3 h. The solvent was partially evaporated, and the mixture was extracted with ethyl acetate (3 x 100 mL), which was then concentrated in vacuo after dried over Na2SC>4. The resulting crude was purified by column chromatography using 5-10% ethyl acetate in hexanes to give compound 7 (2.89 g, 78%). f H NMR (CDCb, 600 MHz): d ppm 3.93 (s, 3H), 3.95 (s, 3H), 6.94 (d, J = 8.4 Hz, 1H), 7.06 (d, ,/ = 1.8 Hz, 1H), 7.11 (dd, J = 8.4, 2.4 Hz, J H), 7.42-7.43 ( , 2H), 7.54 (dt, ,/= 8.4, 1.8 Hz, 2 H),
[0082 [ 4. l-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(3t,4t-dimethoxy-[l,l '-biphenylj-4- yDpiperazine
|0 S3| The mixture of intermediate 4 (3.33 g, 13,6 mmol), intermediate 7 (2 g, 6.8 mmol), B1NAP
(0.425 g, 0,68 mmol ), and CS2CO3 (6,67 g, 20.5 mmol) in toluene (60 mL) was degassed by bubbling N2 for 5 min. Then PdfOAcb (115 mg, 0.51 mmol) was added quickly followed by
degassing for another 5 min. The reaction mixture was refluxed at 110 °C for 24 h under inert condition. Afterward, it was cooled to room temperature, filtered through a pad of eeliie, washe with CH2CI2» and concentrated in vacuo. Hie resulting crude was purified by column chromatography using 10-30% ethyl acetate in hexanes to give compound 8 (2 4 g, 77%). lH NMR (CDCb, 600 MHz): d ppm 0 80 (s, 6H), 0 91 (s, 9H), 2.60 (t, J 6 6 Hz, 2H), 2 71 (t, J = 4.8 Hz, 4H), 3.24 (t, ,7= 4.8 Hz, 4H), 3.81 (t, J = 5.4 Hz, 2H), 3.91 (s, 3H), 3.94 (s, 3H), 6.91 (d, J = 7.8 Hz, IH), 6,97 (d, ,/ = 8,4 Hz, 2H), 7 07-7 11 (m, 2H), 7,46 (d, J = 7.8 Hz, 2H)
100841 5. 2-(4-(3\4'-dimethoxy-[I,l rtbiphenylM-yi)piperazin-l-yl)ethanol
|00851 Compound 8 (2 g, 4 4 mmol) was dissolved in THF (25 mL) and cooled to 0 °C TBAF (n- tetrabutylammonium fluoride) 1 M in THF (8 76 mL, 8.76 mmol) was added at 0 °C, and reaction stirred at room temperature for 2 h. After reaction was complete, saturated NaHCC solution (50 mL) was added, and reaction mixture was extracted with CH2CI2 (3 x 150 mL), which was then concentrated in vacuo. The resulting crude was purified by column chromatography using 0-5% methanol in CH.-Ch to give compound 9 ( 1 34 g, 89%).’FI NMR (CDCb, 600 MHz): <5 ppm 2.63 (t, J 5.4 Hz, 2 I), 2.71 (t, J - 5.4 Hz, 4H), 3.26 (t, J - 4.8 Hz, 4H ), 3.68 (I, .7 - 5.4 Hz, 2H), 3.92 (s, 3H), 3.94 (s, 3H), 6.92 (d, ,7 - 8 4 Hz, HI), 6.86 f d. ,7 - 9 0 Hz, 2H), 7.07-7.1 1 (m, 2H), 7.47 (d, J - 9.0 Hz, 21 1 ).
10086] 6. 2-(4-(3',4'-tiimeth oxy- 11 ,G- biphenyl] -4- i)piperazln- 1 -yl)aeeta tdehyde
10087J A solution of DMSO (0 31 mL, 4 37 mmol) in CH2CI2 (2 mL) was added into a round- bottom flask containing a stirring solution of oxalyl chloride (0.21 mL, 2.41 mmol) in (U A L (2 mL) at -78 °C, The mixture was stirred for 0.5 h at the same temperature, and compound 9 (0.42 g, 1.23 mmol) in CH2G2 (3 mL) was added. The stirring of the reaction mixture was continued at -78 °C for another 0.5 h. Thereafter, EtsN (1 ,38 mL, 9.90 mmol) was added, and the reaction was allowed to warm to room temperature and continued for another 1 h. The reaction mixture was quenched by the addition of a saturated solution of NaliCOi at 0 °C and was extracted with CH2CI2 (3 x 100 mL). The combined organic layer was dried over NajSCL, and the solvent was removed in vacuo to produce the crude, which was purified by column chromatography using ethyl acetate to give compound 10 (0.379 g, 91%). ¾ NMR (600 MHz, CDCb): d ppm 2,73 (t, J = 4.8 Hz, 4H), 3.27 (s, 2FI), 3.30 (t, J 4.8 Hz, 4H ), 3.92 (s, 3H ), 3.94 (s, 3FI), 6.92 (d, J - 8.4 Hz, 1H), 6.98 (d, J- 9 Hz, 2 FI), 7.07-7.11 (m, 2H), 7.47 (d, J = 9.0 Hz, 2H), 9 76 (s, 1 11 ).
|00S8| Procedure A. 1 a. 2-(4-(3\41 '-di methoxy-[ 1 ,1 '-bip hen !] -4-y t)piperazin-l-yl)-N,N- dieth lethanamine
100891 Into a stirring solution of amine 11a (38.4 pL, 0.37 mmol) in CH2G2 (10 mL) was added aldehyde 10 (127 mg, 0.37 mmol), and the mixture stirred for 1.5 h. NaBHfOAefi (0.158 g, 0.75 mmol) was then added portion-wise. The reaction was stirred for 48 h at room temperature. The reaction mixture was quenched with a sat, NaHCCb solution at 0 °C and extracted with CH2CI2 (3 x 30 mL). The combined organic layer was dried over NasSCfi, and solvent was removed under reduced pressure. The crude product was purified by column chromatography using 0-10% MeOH in CH2CI2 to give compound 12a (127 mg, 86%). ¾ NMR (600 MHz, CDClj): d ppm 1.08 (t, 7.2
Hz, 6H), 2.59-2.73 (m, 12 H), 3.25 (t J = 5.4 Hz, 4H), 3.91 (s, 3H), 3.94 (s, 3H), 6 91 (d, J = 8.4 Hz, 1 H), 6.96 (d, J - 8.4 Hz, 2H), 7.07-7.11 (m, 2H), 7.46 (d, J ~ 9.0 Hz, 2H ).
[0090| 1 h. N- (2-{4-{ 1 , ' - di m et h o xy- [ 1 , 1’-biphenyl] -4-y i)piperazm-l-yI)ethyl)-N- isopropyipropan-2-amine
[0091 ] Aldehyde 10 (194 mg, 0.57 mmol), amine lib (80.5 mT, 0.57 mmol), and MaBH(OAc)3
(0.242 g, 1.14 mmol) in CH2CI2 (10 mL) were reacted using procedure A, and the resulting crude was purified by column chromatography using 0-10% MeOH in CHAT to give compound 12b ( 1 17 mg, 48%) Ή NMR (600 MHz, CDCh): S ppm 1 ,08 (bs, 12B), 2.45-2.81 (m, 8H), 2.98-3.16 (m, 2H), 3.25 (t, J= 4.2 Hz, 4H), 3.92 (s, 3H), 3.94 (s, 3H), 6.91 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 9.0 Hz, 2H), 7,07-7,10 (m, 2H), 7.46 (d, J= 8.4 Hz, 2H),
[0092] lc. 2-(4-(3(4’-diiiiethos;y-[l,l’-biphei3yl]-4-yl)pipetazln-l-yl)- -(4- fhiorobetzyl)ethanamine
[0093] Aldehyde 10 (185 mg, 0 54 mmol), amine lie (61.7 pL, 0.54 mmol), and NaBH(OAc);, (0.23 g, 1.09 mmol) in Cl bCT (10 mL) were reacted using procedure A, and die resulting cmde was purified by column chromatography using 0-10% MeOH in CH2CI2 to give compound 12c (73 mg, 30%). l H NMR (600 MHz, CDCh): ppm 2.59 (t, J 6.0 Hz, 6H), 2.75 (t, J - 6.6 Hz, 2H ), 3.22 (t, J ~ 4.8 Hz, 4H), 3.81 (s, 2H), 3.91 (s, 3H), 3.94 (s, 3H), 6.91 (d, J 8.4 Hz, 1 H), 6.97 (d, J- 8.4 Hz, 2H), 7,02 (t, j = 8,4 Hz, 2H), 7,07-7, 1 1 (m, 211), 7.31 (dd, J = 8.4, 5.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H),
[0094J Procedure B. 2a (D-690). 4'-[4-(2-DiethyIamiiio-ethyI)-piperaziii-l-yi]-biphenyl-3,4-dioI (D-690)
[0095] Compound 12» (44 mg, 0.11 mmol) was treated wit 48% hydrobromic acid (2,5 niL) and refluxed for 6 h, HBr was removed to obtain the residue, which was then dissolved in MeOH and filtered through cotton. The filtrate was concentrated and washed with ether for three times followed drying to give the hydrobromide salt of compound 13» (D-690) (63.5 mg, 89%). ¾ NMR (600 MHz, CD3OD): S ppm 1 .40 (t, J = 7.2 Hz, 6H), 3.31 -3.94 (m, 16H), 6.78 (d, J = 7,8 Hz, IH), 6.91 (d, J = 8.4 Hz, 1H), 7.00 (d, J = 2 4 Hz, 1H), 7.10-7.31 (m, 2H), 7,52 (d, ./ = 8.4 Hz, 2B). Mp 198-200 °C. Ana. (CaahHsBrjNiO^) C, H, N.
[0096] 13b (D-687). 4,-i4-(2-Diisopr«pylamin«-ethyl)-piperazin-l-yl]-biphenyl-3,4-diol (D-687)
[0097] Compound 2b (41 mg, 0.096 mmol ) was treated with 48% hydrobromic acid (2 2 ml,) and refluxed for 6 h by following procedure B. The crude was washed with ether for three times followed drying to give the hydrobromide salt of compound 13b (D-687) (49.6 mg, 75%)’H NMR (600 MHz, CDsOD): d ppm 1.46 (s, 6H), 1.47 (s, 6H), 3.34-3.90 (m, !4H), 6.79 (d, J = 7.8 Hz, I H), 6 90 (d, J - 8.4 Hz, IH), 7.00 (s, I H), 7.18-7.28 (m, 2H), 7.51 (d, J - 8.4 Hz, 2H). Mp 168-171 °C. Ana. (GMH43B13N3O15) C, H, N.
I00981 2c (D-688). 4’- {4- [2-(4- Fluoro-benzyl aniin o)-ethyi [ -piperazin-l-yl} -b iphenyl-3,4-dioI (D-
688)
[0099] Compound 12c (63 mg, 0. 14 mmol) was treated with 48% hydrobromic acid (3.2 l.) and refluxed for 6 h by follow ing procedure B. The crude was washed with ether for three times followed drying to give the hydrobromide salt of compound 13c (D-688) (80.5 mg, 82%).’H NMR (600 MHz, CD3OD): S ppm 3 59-3.72 (m, 12H), 4,39 (s, 2H), 6 82 (d, <7 = 7.8 Hz, I H), 6 93 (d, J = 6.6 Hz, IH), 7.03 (d, J = 1.8 Hz, IH), 7.20-7.25 (m, 4H), 7,53 (d, J = 9,0 Hz, 2H), 7,69-7,71 (m, 2H). Mp 200-203 °C. Ana, (C2i¾5Br3F 304) C, H, N.
[00100] Modulation of Alpha synuclein study
[00101] We assessed the ability of our compounds, D-687 and D-688, to alter aggregation and cytotoxicity after co-incubating oSN with these drugs for 6 days followed by evaluation of ThT fluorescence activity and cell viability experiment with the PC 12 cells. A total inhibition of ThT
activity was observed at day 6 in the presence of these compounds compared to LJSN alone, indicating alteration of the aggregation process in the presence of drugs in order to maintain identical condition, cellular viability was determined by using samples from various experiments diluted to maintain final concentration of 10 mM of aSN and 20 mM of drugs. Treatment with preaggregated aSN alone showed a reduction of cell viability by -- 40%
100102] Figure 2 provides (A) inhibition of aSN tibrillization by D-687 and D-688. The drugs were incubated with aSN over a period of six days and the fibrilization was measured by ThT fluorescence assay. Data Values shown are means ± SEMs of three independent experiments, (B) PC 12 cells were treated with 10 mM prefabricated aSN aggregates formed in presence of drugs collected at day 0 and day 6. Values shown are means ± SEMs of three independent experiments performed in 4-6 replicates. One way ANOVA analysis followed by Tukey's Multiple Comparison post hoc test were performed. (*p<0.0l compared to the control).
|00103 j Modulation of amyloid beta aggregation:
|00104| We next evaluated effect of our compounds on modulation of aggregation and disaggregation activity of Ab 1-42 peptide.
100105] Figure 3 A and 3B show inhibition and dissociation of Ab oligomer formation by : a) ThT fluorescence of Ab 1-42 (10mM) with or without incubation with test compounds (20mM) for 24 h. The ThT fluorescence of Abi- 2 at Oh was taken as 100%. b) Abi-42 fibrils (10mM) were incubated with test compounds (20mM) for a period of 24h. The ThT fluorescence of Abi-42 aggregates at Oh was considered as 100%
100106] Similar to the effect of the drugs on a-syn, interaction of compounds with Abi-42 peptide clearly indicated a significant effect in inhibiting aggregation in a time dependent manner as indicated by decrease in ThT activity (Figure 3a). Similarly, test compounds were able to decrease ThT activity of preformed Ab aggregates in a time dependent manner, reflecting its effect in disrupting structure of aggregates (Figure 3b). On the other hand, incubation of aggregates itself led to a gradual increase in ThT activity (Figure 3b). Therefore, test compounds exhibited dual activity in inhibiting association of Abί-42 to form aggregates and in dissociating the formed aggregates. jOOl 07] Conclusion: The overall results indicate the compounds D687, D688 and D690 potently inhibited aggregation of aSN protein and Abi-42 peptide and disaggregate Abh¾ .
100108] IL Scheme 2
100109] L4-Bis(chloromethyl)-2,5-dimethoxybenzene (2): Paraformaldehyde (3.3 g, 108,6 mmol) was added to a slurry of compoun 1 (5.0 g, 36,2 mmol) in cone HC1 (15 mL) and acetic acid (15 mL) at rt under inert gas atmosphere. The mixture was sonicated for 2h, Hie mixture was filtered and the solid w¾s washed with hexane (3 X 50 mL) followed by acetone (15 mL). The crude product was purified by column chromatography using 5% ethyl acetate in hexane to affor compound 2 (5.53 g, 23.53 mmol, 65%) as white solid. JH NMR (600 MHz, CDCL): d 6.92 (s, 2H), 4.63 (s, 4H), 3.85 (s, 6H). fOOI 10] 2,2'-(2,5-Dmietho\y-l ,4-phenylene)diacetonitrile (3): To a mechanically stirred suspension of NaCN (3.45 g, 70.46 mmol) in anhydrous dimethyl sulfoxide was added in small portions of 2 (7.1 1 g, 30 24 mmol). The reaction mixture was stirred at 50 °C for !h. Temperature was increased to 85 °C and the reaction mixture was allowed to stir at that temperature for additional 5 minutes. The mixture was cooled to rt. The reaction mixture was diluted with water (100 ml.) and extracted with ethyl acetate (3 X 150 mL). The combined organic layer was washed with water, brine, dried over NajSOi, and solvent was removed under vacuum. Crude product was purified by column chromatography using 20% ethyl acetate in hexane to give compound 3 (4 57 g, 21.17 mmol, 70%) as white solid, 5H NMR (600 MHz, CDCb): 6 6,92 (s, 211 ), 3.85 (s, (41 ), 3.70 (s, 4H),.
|001H | 2,2'-(2,5-Dimethoxy-l,4-pheiiyIene)diaeetic add (4): To a suspension of compound 3 (0.40 g, 1.85 mmol) in cone. HC1 (10 mL) was added acetic acid (1 mL). The mixture was allowed to stir at 100 °C for 3 h. After completion of the reaction as indicated by TILL the mixture was cooled to rt. The mixture of acids was removed under low pressure. The crude residue was extracted with ethyl acetate (70 mL) and washed with water (3 X 20 mL) The organic layer was washed with brine and dried over NasSCL. The solvent was removed under vacuum. Crude product was purified by column chromatography using 10% methanol in dich loro me thane to give compound 4 (0.28 g, 1,1 1 mmol, 60%) as brown solid. !H NMR (600 MHz, %-D SOf. 5 12 14 (brs, 2H), 6.82 (s, 2H), 3.66 (s, 6H), 3.65 (s, 4H).
100112] Dimethyl 2,2*-(2,5-dimethoxy-l,4-phenylene)diacetate (5): To a suspension of the acid 4 (.1.0 g, 3.93 mmol ) in methanol (25 mL) was slowly added thionyichloride (4,85 mL 66.86 mmol) at 0 °C The mixture was allowed to stir at that teperaiue for 1 h. Then the reaction temperature was graduall increased to it and the stirring was continued for 24h. Solvent and excess reagents were
removed under low pressure. The crude residue was extracted with ethyl acetate (120 mL) and washed with saturated aqueous NaHCCb solution (40 iuL) The organic layer was washed with water (3 X 30 mL), brine and dried over Na2S04. The solvent was removed under vacuum. Crude product was purified by column chromatography using 3% methanol in dichloromethane to give compound 5 (0.61 g, 2,16 mmol, 55%) as white solid. lE NMR (600 MHz, CDCb): 6 6.74 (s, 2H), 3.77 (s, 6H), 3.68 (s, 611 ), 3.61 (s, 414 ).
]001131 2,2,-(2,5-Dimethoxy-l ,4-pheny lene)diethanol (6): To a stirring solution of the ester 5 (0,56 g, 2.0 mmol) in THF (20 mL) was added LiAlH4 (0,30 g, 8.0 mmol) in portions at 0 °C under inert ga atmosphere and the stirring was continued for 1 h. The reaction temperature was increased to rt and the mixture was allowed to stir for overnight. The reaction was quenched with the addition of water (3 mL) fol lowed by 2 N aqueou NaOH (3-5 mL) at 0 °C. The mixture was filtered through cellte and the solid residue was washed with THF (2 X 20 mL) followed by hot ethyiacetaie (40 mL). The combined solution was evaporated under vacuum. Crude product was purified by column chromatography using 3% methanol in dichloromethane to give compound 6 (0.25 g. 1 10 mmol, 55%) as white solid ¾ NMR (600 MHz, CDCb): 6 6.71 (s, 2H), 3.82
6.6 Hz, 4 H), 3.78 (s, 6
H), 2.87 (t, J = 6.6 Hz, 4 H).
100114] 2,2'-(2,5-Dimethoxy- -phenylene)diacetaidehyde (7): To a stirring solution of 6 (50 g,
0.22 mmol) in DCM (10 mL) was added Dess-Martin periodinane (280 mg, 0.66 mmol) at rt. After stirring the reaction mixture for 4 h the volume of the mixture was reduced to half under low pressure. Ii was then passed through celite and the solid was washed with DCM (2 X 7 mL), The combine filtrate was evaporated to produce a soli residue which was purified by column chromatography using 25% ethySacetate in hexane to give compound 7 (29 mg, 0 13 mmol, 60%). lH NMR (600 MHz, CDCb): 6 9 68 (t, J = 1.8 Hz, 2H), 6 71 (s, 2H), 3 77 (s, 6H), 3.65 (d, J= 1.8 Hz, 411 ).
100115] (2,S,,2,A)-,V,A,-((2.5-dimethoxy-L4-pheHylene)bis(ethane-2,l-diyl))his(5-metho\y-]N- propyl- 1,2, 3 ,4-tetrahydronaphthalen-2-a mine) (9): Into stirring solution of compound 7 (47 mg, 0.213 mmol) in DCM (6 mL), (S)-5 -methoxy- A'-propyl - 3 ,2,3 A -tc trail ydronaphthal en-2 -amine (8) (93 mg, 0.422 mmol) was added at room temperature. The reaction mixture was stirred for 1 h, and then NaBH(OAc)i (161 mg, 0.759 mmol) was added into the solution. After stirring for 40 h, saturated solution of NaHCOj (6 mL) was added into the reaction mixture and the compound was extracted with DCM (3 x 10 mL) The combined organic layer was washed with water and brine and
finally purified by silica gel column chromatography (60% EtOAc in hexane) to yield compound 9 (33 mg, 0.05 m ol, 25%.). Ή NMR (600 MHz, CDCh): 8 7 08 (dd, J¾ = 8.4 Hz, J2 = 7.8 Hz, 2H), 6.71 (d, ./ = 7.8 Hz, 2H), 6.66 (s, 2H), 6,65 (d, J= 8.4 Hz, 2H), 3.80 (s, 6H), 3.77 (s, 6H), 3.01 -2.86 (m, 6H), 2 77-2 72 (m, 8H), 2.56-2.50 (m, 6H), 2.11 (m, 2H), 1.66-1 ,55 (m, 8H), 0,9! (t, ,/ = 7.2 Hz, 6H) 13C NMR (150 MHz, CDCh): 5 157.2, 151.3, 138.2, 127 4, 126.1 , 125.3, 121.6, 113.5, 106.8, 56.8, 56.1 , 55,2, 52.7, 51.1 , 32.5, 30.5, 25.8, 23.8, 22.1, 12.0.
[00116 j 2,5-Bis(2-(((S)-5-hydroxy-l ,2,3,4-tetrahydronaphthalen-2- yI)(propyl)amino)ethyl)benzene-l,4-diol (10): A mixture of compound 9 (30 mg, 0,048 mmol) an 48% aqueous HBr (6 mL) was refluxed for 6 h. The reaction mixture was then evaporated to dryness in vacuum. The crude mixture was then washed with diethyl ether to afford compound 10 as a brown solid (31 mg, 0.042 mmol, 88%). l H NMR (600 MHz, CD3OD): 5 6.96 (t, J = 7.8 Hz, 2H), 6.70-6.69 (m, 2H), 6.63-6.60 (m, 4H), 3.79-3.76 (m, 2H), 3.52-3.46 (m, 2H), 3.39-3.32 (m, 4H), 3 24-3 16 (m, 4H), 3.09-2.95 (10H), 2.66-2.56 (m, 2H), 2.40-2.32 (m, 2H), 1.89-1.78 (m, 6H), 1.05 (t, J - 7.2 Hz, 8H).
|00117] C. Scheme 3 (Figure 5) fOOl lSj 2,2,-(2,5-Dimetho\y-i,4-phenylene)diacetaldehyde (7), To a stirring suspension of alcohol
6 (0.12 g, 0.53 mmol) in CH2CI2 (10 mL) was added Dess-Marlin periodinane (0.675 g, 1.59 mmol) at room temperature. After stirring the reaction mixture for 4 h, it was filtered through a pad of eelite, washed with CH2CI2 and the combine filtrate was evaporated to produce a solid residue. The crude product was purified by silica gel column chromatography (hexane;ethyl acetate :::: 3:1 ) to give aldehyde 7 (0.1 g, 85%). The purified aldehyde was used immediately for next step. * H NMR (600 MHz, CDCh): d 9.69 (s, 1H), 6.73 (s, 2H), 3,78 (s, 6H), 3.66 (d, J = 1.8 Hz, 4H)
|00119j 2,5~bis(2-(((A)-2~amino-4,5,6,7-tetrahydrohenzo|f/3thiazol-6-yl)(propyl)amino>
ethyi)benzene-i,4-diol (11).
[001201 into a stirring solution of aldehyde 7 (0.09 g, 0.41 mmol ) in ChfiCfi (10 mL) was added (S)- L6 -propyl-4,5, 6, 7-tetrahydrobenzo[if|thiazoie-2, 6-diamine (0. 154 g, 0 73 mmol). Alter the mixture was stirred for 1.5 h, NaBH{OAcb (0.343 g, 1.62 mmol) was added portion wise and the mixture was stirred for 48 h at room temperature. The reaction mixture was quenched with a saturated solution of NaHCCh at 0 °C and extracted with CTfiCfi (3 * 40 mL). The combined organic layer was dried over NajSCh, and the solvent was removed under reduced pressure. Crude product was
purified by column chromatograph (EtOAc/MeOH 8:1) to afford compound 11 (0.085 g, 34%). 1H NMR (600 MHz, CDCh): S 6 65 (s, 2H)S 5 19 (bs, 4H)S 3 77 (s, 6H)S 3 13-3 07 (m, 2H), 2.73-2,67 (m, 121 1 ). 2.59-2.49 (m, 8H), 2.01-1.99 (m, 21 1 ). 1.74-1.68 (m, 21 1 ). 1.54-1.48 (m, 4H), 0.90 (t, J = 7.2 Hz, 6H); °C NMR (150 MHz, CDCb): <5 165,91, 151.21 , 144,84, 127.20, 117 10, 1 13,45, 60,41 , 57.79, 56.08, 52 91, 51 .24, 30.71, 26.48, 25.94, 25.12, 22.15, 14 18, 1 1 .90; [a]o2S- -55.2 (c=1 .0 in CH2CI2).
|00121 j 2,5-M$(2-(((^ 2-ammo-4,5,6,7-tetrahydrobenzo[i^thiazo!-0-yl)(propyi)amino)- ethyl)benzene- 1 ,4-diol (12) (D- 73), A mixture of compound 11 (0.075 g, 0.12 mmol) and 48% aqueous HBr (15 mL) was refluxed at 130 °C for 5 h. The reaction mixture was evaporated to dryness, washed with ether followed by vacuum drying to yield HBr salt of 12 (0.105 g, 95%).
NMR (600 MHz, CD3OD): S 6.77 (s, 2H), 4.03 (s, 2H ), 3.55-3.33 (m, SH ), 3.27-3.23 (m, 2H ), 3.14 (i, J :- 10.2 Hz, 2H), 3.04 (t, J 7.8 Hz, 4H), 3.00-2.94 (m, 2H), 2.78 (bs, 4H), 2.47-2.41 (m, 2H), 2.18-2.11 (m, 2H), 1.94-1.83 (m, 4H), 1.04 (t, J - 7.2 Hz, 6H);“C NMR (150 MHz, CD3OD): <5 173.95, 151 .96, 136.64, 126.43, 120.98, 115.79, 63.10, 62.86, 57.37, 56.82, 54.90, 52.45, 29.99, 27.01, 26.16, 25.54, 22.26, 13.99; [ofo25- -42.0 (c=1.0 in CH3OH); Anal. Calcd for IsiBrsNeOsSi: C, 35.77; H, 5.10; N, 8.34. Found: C, 36.08; H, 5.42; N, 8.27.
[001221 Table 1. Inhibition constants determined by competition experiments assessing j 3 II [spiroperidol binding to cloned Du and D receptors expressed in i lEK-293 cells'1
‘“Results are the mean ± SEM of 3-6 experiments, each performed in triplicate.
|00123 j Table 2. Stimulation of [3SS]GTPyS binding to clone human D2 and D? receptors expressed in CHO cells0
[00124] the concentration producing half maximal sti ulation. For each compound, maximal stimulation (£max) is expressed as a percent of the £m ax observed with I mM (Da) or 100 mM (Dy) of the full agonist DA (Emax., %). Results are the mean ± SEM for 3-6 experiments, each performed in triplicate. 00125j D, Scheme 4 (Figure 6)
[00126] Synthesis of P-679
[00127] iV-(2,5-Dioxo-tetrahydro-furan-3-yI)-2,2,,2-trifUioro-acetamide (1), Trifluoroacetic anhydride (13.12 mL, 93.91 mmol) was added to D-aspartic acid (5,0 g, 37.57 mmol) at -60 °C and stirred for 10 min. The reaction mixture was allowed to warm to room temperature and then to 40 °C during which a vigorous exothermic reaction took place. Trifluoroacetic acid (10 mL) was added next and the reaction mixture was stirred under refluxing condition for 2 h. After cooling, petroleum ether was added and the soli thus formed was collecte by filtration, washe successively with petroleum ether and ether and finally dried under vacuum to afford compound 1 (7 7 g, 97%), 1H NMR (600 MHz, Acetone-D*): <5 9 41 (bs, I B), 5.30-5.26 (m, 1 H), 3.53 (q, J = 10.2 Hz, 1H), 3.27 (dd. J 12.0, 6.6 Hz, I B).
[00128] 4-(3,4-Dimethoxy-phenyI)-4-oxo-2-(2>2,2-trif1uoro-acet\iamino)-hutyric acid (2). To a stirring suspension of compound 1 (4.0 g, 18.95 mmol ) and AlCh (6 3 g, 47.37 mmol ) in Cl LCl· (90 ml), verairole (3.62 mL, 28,42 mmol) was added an the reaction mixture was stirred at room temperature for 4 days. 6M HC1 was added to the reaction vessel and the layers were separated. Aqueous layer was extracted with ether (3 x 50 mL) and the combined organic portions were dried over Na^SCfi, filtered and evaporated under reduced pressure. The crude materia! was purified by silica gel column chromatography (hexane: EtO Ac 1 : 1) to give compound 2 (5.3 g, 80%). 1H NMR (600 MHz, CDCb); S 7.61 (bs, 1 H), 7.58 (d, J = 8.4 Hz, 1 H), 7.48 (s, IH), 6.92 (d, J = 8.4 Hz, 1 H), 5.02-5.00 (m, 1H), 3.97 (s, 3i¾ 3.93 (s, 3H), 3.89-3.86 (m, IH), 3.58 (dd, J 14.4, 4.2 Hz, IH).
[00129] 4-(3,4-Dhnethoxy-phenyI)-2-(2,2.,2-trifluoro-acetyIaimno)-butyric acid (3). Triethylsilane
(9.7 mL, 60.7 mrnol) was added to a magnetically stirred solution ofketo acid 2 (5 3 g, 15,18 mmol)
in trill uoroacetic acid (22.5 mL, 303.5 mmol). This solution was boiled under reflux under M? for 2 h after which it was cooled and carefully neutralized to pH 8 with NaHCCh solution at 0 °C. The aqueous solution was washed twice with Et20 and acidified (pH <5) b the dropwise addition of 6N HC1 at 0 °C. The product was extracte with EtiO (3 x 30 mL), the organic layers were dried over MgSCk, and the ether was removed by rotary evaporation to yield a yellow oil. which solidified on standing. This solid was recrystallized from EtO Ac/hexane to afford carboxylic acid 3 (4.7 g, 92%). ¾ NMR (600 MHz, CDCT): 0 6.81 (d, J = 8.4 Hz, IH), 6.74-6.71 (m, 2H), 6 70 (d, J = 1.2 Hz, IH), 4.73-4.70 (m, IH), 3.87 (s, 3H), 3.86 (s, 3H), 2.68 (t, J = 7.2 Hz, 2H), 2.37-2.31 (m, I H), 2.21- 2.15 (m, I H ).
[00130] A-(6,7-Diraethoxy-l-oxo-l,2,3s4-tetrahydro-naphthaIen-2-yl)-2,2s2-trifluoro-acetamide (4). To an ice-cooled solution of compound 3 (4.5 g, 13.42 mmol) in 40 ml. of O bC k was added solid PCI5 (3.35 g, 16.1 1 mmol). Stirring was continued for 1 h at 0 °C, and SnCU (3.14 mL, 26.84 mmol) was added. The mixture was stirred for 0.5 h at 0 °C and then allowed to warm to room temperature and stirred for an additional 4 h. The mixture was poured into ice water and vigorously stirred for 15 min. The layers were separated, and the aqueous phase was extracted with CH2CI2 (3 x 50 mL) The organic portions were dried over MgSCL and rotary evaporated to furnish white solid, which was purified by silica gel column chromatography (hexane:EtOAe = 3:2) to give colorless tetralone 4 (2.5 g, 59%). lH NMR (600 MHz, CDCh): d 7.58 (bs, 1H), 7.46 (dd, .7 = 3.6, 1.2 Hz, 1 H), 6.69 (s, 1H), 4.58-4,54 (m, 1 H), 3.96 (s, 3H), 3,93 (s, 3H), 3 26-3 20 (m, 1 H), 2.99-2.96 (m, I H). 2.89-2.85 (m, 1H), 1.95 (dq, ./ = 9.0, 4.8 Hz, 1H).
[00131] A'-(0,7-Dimethoxy-l,2,3,4-tetrahydro-naphthalen-2-yl)-2,2,2-tnfUioro-aeetamide (5).
Triethylsiiane (4.53 mL, 28.37 mmol) was added to a solution of compound 4 (2.25 g, 7.09 mmol ) in 17,5 mL (141.84 mmol) of Bfd.Et^O, and the resulting solution was stirred at room temperature under N2 for 48 h. Alter basification of the mixture by addition to saturated NaHCCh, the layers were separated, and the product was extracted with H O (3 x 50 mL). Tire combined organic layers were dried over NajSCL and concentrated on a rotary evaporator. The crude residue was purified by silica gel column chromatography (hexane:EtOAc = 7:3) to afford compound 5 (1.65 g, 77%). lH NMR (600 MHz, CDCh ): S 6.59 (s, IH), 6.55 (s, Hi), 6.34 (bs, IH), 4.37-4.30 (m, 111). 3,85 (s, 3H), 3.84 (s, 3H), 3.11 (dd, ./ - 1 1.4, 4.8 Hz, IH), 2.90-2.85 (m, IH), 2.83-2.78 (m, IH), 2.67 (dd, J = 8.4, 7.8 Hz, 1H), 2.1 1 -2.06 (m, 1 H), 1.91-1.85 (m, 1H).
[00132] 6,7-Dimethoxy-l,2,3,4-tetraliydro-iiaphthalen-2-y!amlne (6). To a stirred suspension of
K2CO3 (1 37 g, 9 9 mmol) in 30 mL of MeOH containing 1.5 mL of H2O was added triiluoroacetamide 5 (1 ,0 g, 3.3 mmol), and the mixture was boiled under reflux for 4 h. The mixture was allowed to cool to room temperature, and the undissolve K2CO3 was removed by filtration through a cotton plug. The filtrate was concentrated in vacuo, and the dark residue was diluted with water. The product was extracted with EtOAc (3 x 40 mL), the organic layers were dried over NinSCfi and the volatiles were removed by rotary evaporator to furnish compound 6 (0 65 g, 95%). 'll NMR (600 MHz, CD OD): <5 6,62 (s, 1 H), 6,60 (s, IH), 4.87 (bs, 2H), 3.75 is, 611), 3.03-2.99 (m, IH), 2.88 (dd, /= 10.8, 4.8 Hz, 1 H), 2.79-2.72 (m, 2H), 2.45 (dd, J- 9.6, 6.0 Hz, 1 H), 2.00-1.95 (m, Hi), 1.55-1.49 (m, 1H).
[00133] A-{6,7-Dimethoxy-l,2,3,4-tetrahydro-naphthalen-2-yl)-2-nitro-benzenesulfonamkJe (7).
2-Nitroben enesulfony! chloride (0.64 g, 2.89 mmol) was dissolved in 20 mL of THE, and the solution was cooled to approximately -10°C. EfvN ( 1.82 mL, 13.03 mmol) and compound 6 (0 6 g, 2.89 mmol) were added and the resulting suspension was heated during mixing to approximately 25°C, and allowed to react for 1.5 h. Precipitated triethyiammonium chloride was filtered off, and the filtrate was concentrated. Water was added and extracted with EtOAc (3 x 30 mL). The combined organic layer was dried using Na?S04, and the solvent was removed under reduce pressure to obtain sulfonamide 7 (1,05 g, 93%). rH NMR (600 MHz, CDCh): *5 8.21 -8.19 (m, IH), 7.90-7.88 (m, IH), 7,78-7.74 (m, 2H), 6,54 (s, I H), 6.41 (s, IH), 5.40 (d, J = 7 2 Hz, IH), 3.83 (s, 3H), 3.80 (s, 3H), 2.95-2.9.1 (m, IH), 2.81 -2.74 (m, 2H), 2.69 -2.65 (m, I B), 2.01-1.97 (m, I H), 1.83-1.77
[00134] A?-(6,7-Dmiethoxy-l,2,3,4-tetrahydro-naphthalen-2-yI)-2-nitro-A?-propyI-benzene- sulfonamide (8). To a stirred suspension of 7 (1 ,0 g, 2.55 mmol) and potassium carbonate (2.47 g, 17.84 mmol) in acetonitrile (25 mL), 1 -bromopropane (0 69 mL, 7,65 mmol) was added and the reaction mixture was stirred at 40 °C for 48 h. The reaction mixture was cooled to room temperature, fi ltered off and the filtrate was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:EtOAc - 7:3) to afford compound 8 (0.99 g, 89%). lH NMR (600 MHz, CDCH): S 8,09 (dd. J 6,0, 1.8 Hz, Hi), 7.71-7.66 (m, 2H). 7.63 (dd, J - 6.0, 1.8 Hz, I H), 6.55 (s, IH), 6.50 (s, 1 11). 4.12-4.06 (m, IH), 3.83 (s, 3H), 3.82 (s, 3H), 3.28 (t. J 7.8 Hz, 2H ), 2,96-2,78 (m, 111 ). 2.01-1.98 (m, I H), 1 87-1.80 (m, IH), 1.74-1.64 (m, 2H), 0.90 (t, J - 7.2 Hz, 3H); [a]»25- +75.4 (c-1.0 in CH2CI2).
[00135] {6,7-Dimethoxy-l,2,3i4-tetrahydro-naphthaien-2-yl)-propyl-amlne (9)- Into a mixture of potassium carbonate (1 ,63 g, 11 ,81 mmol) in 20 mL of DMF, thioglycolie acid (0.47 mL, 6,56 mmol) was added slowly at 0 °C The mixture was stirred a room temperature for approximately 1 h, followed by addition of compound 8 (0.57 g, 1 ,31 mmol, in 10 mL of DMF), The reaction mixture was heated during stirring to about 50 °C and allowed to react for an additional 15 h, after which it was quenched by addition of 1N NaOH and extracted with EtOAc (4 x 25 mL). 'fhe combined organic layer was dried using Na2S04, and the solvent was concentrated under reduced -pressure. The crude product was purified by silica gel column chromatography (0-10% MeOH in CH2CI2) to give compound 9 (0 22 g, 67%). Hi NMR (600 MHz, CDCh): S 6.56 (d, J === 5.4 Hz, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 2.99-2.91 (m, 2H), 2.82-2.76 (m, 2H), 2.71 (t, J - 7.8 Hz, 2H ), 2.60-2.56 (m, 2H), 2 08-2 06 (m, 1H), 1.66-1.55 (m, 3H), 0.95 (t, J- 7.2 Hz, 3H); a]D 25-+68.6 (c=L0 in CH2CI2).
|OOI36j Procedure A. (4-{i(5-Methoxy-l,2»3 4-tetrahydro-naphthalen-2-yl)-propyl-carbamoyl]- methyl}-phenyl)-acetic acid (10). To a solution of 1 ,4-phenylenediacetic acid ( 1.0 g, 5.15 mmol) in DMF (20 mL) were added EDO (0.296 g, 1.54 mmol), HOB (0.21 g, 1 .54 mmol ) and Et.iN (0.25 mL, 1.80 mmol) and the resulting mixture was stirred at room temperature for 1 h. (5V5-me hoxy-V- propyl-l ,2,3,4-telrahydronaphthalen-2-amine (0.28 g, 1.29 mmol) in DMF (5 mL) was added next to the reaction mixture and stirred at room temperature for an additional 3 h after which DMF was evaporated under vacuum. Water was added and extracted with CH2O2 (3 x 25 mL). The combined organic layer was drie using Na?S04, and the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatograph (hexaneiEtOAe = 2:3) to yield compound 10 (0.325 g, 64%). lH NMR (600 MHz, CDCh): S 7.24-7.15 (m, 4H), 7.08 (q, ./ = 7.8 Hz, 1 H), 6.66-6.60 (m, 2H), 4.58-4.55 (m, 1H), 4,04-3.99 (m, 1 H), 3 80 (s, 3H), 3.75 (s, 1 H), 3.72 (s, 1H), 3.24-3.12 (m, 2H), 3.02-2.82 (m, 3H), 2.63-2.57 (m, 1 H), 2.40-2.34 (m, 1 H), 1.97-1.94 (m, 1 H), 1.74-1.59 (m, 3H), 0.91 -0.87 (m, 3H),
[00137] 2-(4-{|(6,7-Dimethoxy-l,2,3 4-tetrahydro-naphthaIen-2-yI)-propyI-carbamoyl]-methyI}- phenyI)- V-(5-methoxy-l,2,3,4-tetrahydro-naphthalen-2-yl)-A-propyI-acetaimde (11).
Compound 10 (0.28 g, 0.71 mmol), 9 (0.177 g, 0.71 mmol), EDO (0 136 g, 0.71 mmol), HOBl (0.096 g, 0 71 mmol) and EhN (0 1 mL, 0,71 mmol) were reacted in DMF (15 mL) overnight according to procedure A The crude product was purified by silica gel column chromatography (hexane: EtOAc - 2:3) to afford compound 11 (0 325 g, 73%).
NMR (600 MHz, CDCh): d 7.26- 7.17 (m, 4H), 7.1 1 -7.06 (m, 1 H), 6.67-6.61 (m, 2H), 6.56-6.50 (m, 2H), 4.63-4.57 (m, IH), 4.06-3.99
(m, 1 H), 3.83-3.78 (m, 9H), 3.76-3,71 (m, 411 ). 3.24-3.1 1 (m, 4H), 3.03-2.75 (m, 51 Gk 2.73-2.58 (m, 3H), 2 42-2 31 (m, 1H), 1.97-1.87 (m, 2H), 1.81-1 63 (m, 5H), 0.92-0.87 (m, 6H); [a]h25= +12.4 (c= 1.0 in CH2CI2).
100138] (6,7-Diniethovy- 1.2,3,4-tetrahydro-naphthaien-2-yl)-|2-(4- {2- [(5-methoxy-l ,2.3,4- tetrahydro-naphtha]en-2-yl)-propyl-amino]-ethyl]-pheny])-ethylj-propyl-amine (12). To a solution of compound 11 (0,31 g, 0.5 mmol) in anhydrous THF (10 L), BH3.THF complex (4.95 niL, 4.95 mmol, 1.0 M in THF) was added dropwise at room temperature. Reaction temperature was raised to 55 °C and the mixture was stirred for 4 h, Alter cooling, water (1 mL) and concentrated HC1 (2 mL) were added at 0 °C and then THF was evaporated under vacuum. 25% NaOH solution (20 mL) was added to the aqueous phase and extracted with EtOAc (3 x 25 mL). The combined organic layer was dried using NaaSCU, and the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:EtOAc - 7:3) to furnish compound 12 (0.205 g, 69%) Ή NMR (600 MHz, CDCh): S 7.18 (s, 4H), 7.1 1 -7.08 (m, 1 H), 6.71 (q. ./ - 7.8 Hz, 1H), 6.65 (d, J 8.4 Hz, IK), 6.60-6.56 (m, 2H), 3.84-3.79 (m, 9H), 3.30-3.19 (m, 3H), 3.18-3.04 iroJH). 3.01 -2.73 (m, 10H), 2.57-2.38 (m, 3H), 1 .91-1 .71 (m, 7H), 0.97-0.93 (m, 6H); °C NMR (150 MHz, CDCh); d 157.09, 147.41, 137.12, 136.05, 129.24, 127.09, 126.66, 126.23, 124 19, 121.50, 1 12.03, 111 05, 107.27, 64.44, 64.05, 60.37, 58.72, 55,92, 55.25, 30 13, 29.63, 29.53, 29.45, 24.06, 23.51, 21.05, 16.42, 14.23, 1 1 .88;
100139] 6-{|2-(4-{2-[(5-Hydroxy-l,2,3,4-tetrahyclro-naphthalen-2-yl)-propyI-ammo]-ethyl}- phenyl)-ethyl]-propyl-amino}-5.6,7,8-tetrahydro-naphthalene-2,3-diol (13) (15-679). A mixture of compound 12 (0.2 g, 0,33 mmol) and 48% aqueous HBr (15 mL) was refluxed at 130 °C for 5 h. The reaction mixture was evaporated to dryness, washed with ether followed by vacuum drying to yield HBr salt of 13 (0 22 g, 89%), 1 H NMR (600 MHz, CD3OD): S 7.31 (i, J = 7.8 Hz, 4H), 6.85 (i, J= 7.2 Hz, l H), 6.63 (d, J = 7.8 Hz, 1H), 6.57-6.52 (m, 2H), 6.47 (s, 1 H), 3.64-3.62 (m, 2H), 3.46- 3.32 (m, 111 ), 3.27-3.13 (m, 9H), 3.01-2.88 (m, 4H), 2.68 (bs, 2H), 2.54-2.46 (m, 1 H), 2.32-2.26 (m, 2H), 1 .84-1 .76 (m, 6H), 1.02 (t, - 7.2 Hz, 6H); t3C NMR (150 MHz, CDiOD): d 154.53, 143.73, 143.41 , 135.52, 133.56, 129.27, 126.61 , 125.78, 122.99, 121.73, 120.09, 1 15.39, 1 14.66, 112.24, 60.88, 60.52, 52.57, 52,31, 52.14, 51.82, 30.46, 29.47, 28.66, 27.31, 24,11 , 23.48, 22.36, 18.54, 10.31; [a]tt% t-7.8 (c-0.5 in CH3OH); Anal. Calcd for CwHssBraNsC s: C, 57.99; H, 7.16; N, 3.76. Found: C, 57.94; H, 7.03; N, 3.81.
ί00140| While embodiments of the invention have been illustrated and described it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit an scope of the invention.
Claims
WHAT IS CLAIMED IS:
1 , A compound having formula Ϊ for treating a neurodegenerative disease:
wherein:
Ri is H, Cj-8 alkyl, C2-8 alkenyl, C4-8 cycloalkyl, C4-8 cycloalkenyi, Ce-io aryl. Cj. to alkyl C*.
R2, R , R4, R$ are each independently H or OH wherein at least 2 of R2, Rj, R4, R5 arc OH; Rh is H, an optionally substituted Ci-s alkyl, an optionally substituted C1-8 alkoxyl, an optionally substituted tb-s alkenyl, an optionally substituted C .x alkynyl, an optionally substituted
0..x cycloalkyl, an optionally substituted C..x cycloalkenyi, an optionally substituted Cl -8 alkyl CL
R? is H, an optionally substituted Ct-s alkyl, an optionally substituted Cue alkoxyl, an optionally substituted CLH alkenyl, an optionally substituted C2-S alkynyl, an optionally substituted C4-8 cycloalkyl, an optionally substituted C4-s cycloalkenyi, an optionally substituted Cl -8 alkyl Ce- o aryl or an optionally substituted CS-JO aryl;
Rg are each independently hydroxyl. Ci-4 alkyl, CM alkoxyl, Ci-s alkyl, C2-8 alkenyl, C2-3 alkynyl, CM eycloalkyl, CM cycloalkenyl; CS-JO aryl, -NR-’q or CMO hydrocarbon groups optionally containing one or more O, , S, or Se heteroatoms where R’ individuall are H or organyi groups and q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge;
Z¾Ts is absent or a divalent linking moiety in which Z is repeated m times;
o is 0. 1. 2, 3, or 4; and
m is Q, 1 , 2, 3, 4, or 5.
4 The compound of claim 1 having a formula selected fro the group consisting of:
and pharmaceutically acceptable salts and esters thereof.
13a (D-690) or a pharmaceutically acceptable sail: or ester thereof.
13b (D-687) or a pharmaceutically acceptable salt or ester thereof.
13c (D-688) or a pharmaceutically acceptable salt or ester thereof.
9. The compound of claim 1 wherein R? is substituted with a component selected from the group consisting of, halogen, CM alkyl, Cj-s alkoxy, C acyloxy, CM acyl, -C(0)-R.9, -Rio-NH- SO.i-Ni R / , , -Rjo-NH-C(0)-Ri»; -R i o-N(Ry)r. and -Ry-Ar where
R > is H, Ci-s alkyl, CM alkenyl, C4-s eycioaikyl, CU-s eycloalkenyl, or Cs-io aryl;
Rut is C -s alkenyl;
r is 2 or 3; and
Ar is a C*-io aryl ring system, optionally including one or more heteroatoms or Cs-io heteroaryl; with the proviso that when r is 3. the nitrogen of the CR»),- group will bear a positive formal charge.
10. The compound of claim 9 wherein Ar is an optionally substituted phenyl, thienyl, pyridyl, bipyridyl, biphenylyl, or naphthyl.
1 1. The compound of claim 1 wherein Rs are hydroxyl, halogen, C i -s alkyl, CM alkoxyl, C2-8 alkenyl, C2-8 alkynyl, CM cyeioalkyl, CM eycloalkenyl; C<s-io aryl, -N(Rn)4 -NH-C(0)-Rn, or ~ NH-C(0)-N(Rj 2)2, where Rn individually are H, CM alkyl, C2-8 alkenyl, C2-10 alkynyl, CM cycloalkyl, CM eycloalkenyl, or GS-JO aryl where q is 2 or 3, with the proviso that when q is 3, the group bears a positive formal charge and wherein the hydrocarbon groups in each case are optionally substituted with -ON, CM alkyl, -ORn, -OH, halo, or -CFi where Ru is C alkyl.
12. The compound of clai 1 wherein Z is selected from the group consisting of-CTh-, -
CHOHCB2-, -CHOHCH2CH2-, -CHOHCH2CH2CH2-, -CO-, -N-CH2-, N-CO-, -(CH2 I :- , - CHOH(CH2)n-„ -f CH >),CO-, -(CHRNCOitTT)k-. Cwo carboximido, 2I-JO alkanediyl, C200 alkanediyl,€ >-HJ alkynediyl, and combinations thereof; m is L 2, 3, 4, or 5, and n and k are each independently integers 0, 1 , 2» 3, 4, 5 ,6, 7, or 8,
13, A compound having formula 11 for treating a neurodegen erativc disease:
wherein:
A is an optionally substituted C6-i2 aryl or C6-i2 heteroaryl;
Ri4, Rf s are each independently B. Ci-s alkyl, C2-S alkenyl, Ci-s cycloalkyl, C4-8
cycloaikenyl, Cs-io aryl, Ci-10 alkyl or CTu> ryl;
Bt and B2 are each independently
Rj6 is an optional substituent.
14. The compound of claim 13 wherein A is optionally substituted phenyl .
15. The compound of claim 14 wherein A is a substituted phenyl having 1, 2, 3. or 4 hydroxyl groups.
where Rn, Rie, i¾ R20 are each independently H, Ci-g alkyl, OH, or halo (e.g., F, Cl, Br, 1).
17. The compound of claim 13 wherein A is:
20. The compound of claim 13 having the following formula:
21. The compound of claim 13 wherein Rtf, are hydroxyl, halogen, nitro, cyano, Cj-g alkyl, Ci-s alkoxyl, Ci-s alkenyl, C2-8 alkynyl, C4-S cycloalkyl, C4-8 cycloalkenyl; Cs-to aryl, ~N(Rj 3 )q ~ NH~C(0)~Rn, or -NHC(0)-N(Ri2>2, where Rn individually are H, Ci-s alkyl, C2-8 alkenyl, C2-10 alkynyl, C4-8 cycloalkyl, CU-s cycloalkenyl, or Ce-io aryl where q is 2 or 3, with the proviso that when is 3, the group bears a positive formal charge and wherein the hydrocarbon groups in each ease are optionally substituted with ~CN, Cj-s alkyl, -OR· n -OH, halo, or -CF where RJ 3 is Ct-s alkyl.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3111561A CA3111561A1 (en) | 2018-09-07 | 2019-09-06 | Neuroprotective agents for treatment of neurodegenerative diseases |
EP19858466.6A EP3846816A4 (en) | 2018-09-07 | 2019-09-06 | Neuroprotective agents for treatment of neurodegenerative diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/124,974 | 2018-09-07 | ||
US16/124,974 US10874669B2 (en) | 2012-11-29 | 2018-09-07 | Neuroprotective agents for treatment of neurodegenerative diseases |
US16/154,301 | 2018-10-08 | ||
US16/154,301 US20190038622A1 (en) | 2012-11-29 | 2018-10-08 | Neuroprotective agents for treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020051435A1 true WO2020051435A1 (en) | 2020-03-12 |
Family
ID=69723262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/049927 WO2020051435A1 (en) | 2018-09-07 | 2019-09-06 | Neuroprotective agents for treatment of neurodegenerative diseases |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3846816A4 (en) |
CA (1) | CA3111561A1 (en) |
WO (1) | WO2020051435A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023025138A1 (en) * | 2021-08-24 | 2023-03-02 | 杭州中美华东制药有限公司 | Camptothecin derivative intermediate and synthesis method therefor, and method for synthesizing camptothecin derivative by using intermediate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014085600A1 (en) * | 2012-11-29 | 2014-06-05 | Wayne State University | Neuroprotective agents for treatment of neurodegenerative diseases |
-
2019
- 2019-09-06 CA CA3111561A patent/CA3111561A1/en active Pending
- 2019-09-06 WO PCT/US2019/049927 patent/WO2020051435A1/en unknown
- 2019-09-06 EP EP19858466.6A patent/EP3846816A4/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014085600A1 (en) * | 2012-11-29 | 2014-06-05 | Wayne State University | Neuroprotective agents for treatment of neurodegenerative diseases |
Non-Patent Citations (6)
Title |
---|
DEEPTHI YEDLAPUDI: "Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in viva Drosophila synucleinopathy model", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 December 2016 (2016-12-01), pages 38510, XP055693136, DOI: 10.1038/srep38510 |
DEEPTHI YEDLAPUDI; JOSHI GNANADA S; LUO DAN; TODI SOKOL V; DUTTA ALOKE K: "Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model", SCIENTIFIC REPORTS, vol. 6, no. 1, 38510, 1 December 2016 (2016-12-01), pages 1 - 12, XP055693136, DOI: 10.1038/srep38510 * |
FAHD DHOLKAWALA , CHANDRASHEKHAR , ALOKE K DUTTA : "Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson' s disease", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 103, 1 January 2016 (2016-01-01), pages 62 - 70, XP055693134, DOI: 10.1016/j.ejpb.2016.03.017 * |
GYAN MODI , HORRICK SHARMA , PRASHANT S. KHARKAR . ALOKE K. DUTTA: "Understanding the structural requirements of hybrid (S)-6-((2-(4-phenylpiperazin-1-yl) ethyl)(propyl) amino)-5, 6, 7, 8 -tetrahydronaphthalen-1-ol and its analogs as D2/D3 receptor ligands: a 3D QSAR investigation", MEDCHEMCOMM, vol. 5, no. 9, 19 June 2014 (2014-06-19), pages 1384 - 1399, XP055783830, ISSN: 2040-2503, DOI: 10.1039/C4MD00159A * |
GYAN MODI; VOSHAVAR CHANDRASHEKHAR; GOGOI SANJIB; SHAH MRUDANG; ANTONIO TAMARA; REITH MAARTEN E A; DUTTA ALOKE K: "Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates", ACS CHEMICAL NEUROSCIENCE, vol. 5, no. 8, 24 June 2014 (2014-06-24), pages 700 - 717, XP055693143, ISSN: 1948-7193, DOI: 10.1021/cn500084x * |
See also references of EP3846816A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023025138A1 (en) * | 2021-08-24 | 2023-03-02 | 杭州中美华东制药有限公司 | Camptothecin derivative intermediate and synthesis method therefor, and method for synthesizing camptothecin derivative by using intermediate |
CN115724758A (en) * | 2021-08-24 | 2023-03-03 | 杭州中美华东制药有限公司 | Camptothecin derivative intermediate, synthetic method thereof and method for synthesizing camptothecin derivative by using intermediate |
Also Published As
Publication number | Publication date |
---|---|
EP3846816A1 (en) | 2021-07-14 |
CA3111561A1 (en) | 2020-03-12 |
EP3846816A4 (en) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101486026B1 (en) | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | |
US10059668B2 (en) | LSD1 inhibitors | |
US9637484B2 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
US20120184580A1 (en) | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | |
JP6653410B2 (en) | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | |
NZ550763A (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide | |
US20230150927A1 (en) | Cannabigerol derivatives and use thereof as cannabinoid receptor modulators | |
EP3846816A1 (en) | Neuroprotective agents for treatment of neurodegenerative diseases | |
AU2002331145B2 (en) | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
US10125127B2 (en) | Neuroprotective agents for treatment of neurodegenerative diseases | |
AU2011336217B2 (en) | KAT II inhibitors | |
JPH09502448A (en) | 2-Amino-1,2,3,4-tetrahydronaphthalene derivative active in cardiovascular system | |
US11285147B2 (en) | Neuroprotective agents for treatment of neurodegenerative diseases | |
US20190055212A1 (en) | Histone demethylase inhibitors | |
EP3325452B1 (en) | Substituted hydrophobic benzene sulfonamide thiazole compounds for use in treating cancer | |
US11168074B2 (en) | Potassium channel inhibitors | |
US10874669B2 (en) | Neuroprotective agents for treatment of neurodegenerative diseases | |
US20190038622A1 (en) | Neuroprotective agents for treatment of neurodegenerative diseases | |
WO2023091565A1 (en) | Nsd2-targeted chemical degraders and compositions and methods of use thereof | |
WO2012074784A2 (en) | Novel fluorinated sulfamides exhibiting neuroprotective action and their method of use | |
FR2967413A1 (en) | COMPOUND 8-OXO-9- [3- (1H-BENZIMIDAZOL-2-YLOXY) -PHENYL] -4,5,6,7,8,9-HEXAHYDRO-2H-PYRROLO [3,4-B] QUINOLIN-3 - ETHYL CARBOXYLATE, SALT, CRYSTALLINE FORM, CO-CRYSTAL, FORMULATION, METHODS OF PREPARATION, MEDICAMENT APPLICATION, PHARMACEUTICAL COMPOSITIONS, AND NOVEL USE, IN PARTICULAR AS THE INHIBITOR OF AURORA KINASES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19858466 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3111561 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019858466 Country of ref document: EP Effective date: 20210407 |